close
Health topics

Opportunistic infection

opportunistic infection

What is an opportunistic infection

Opportunistic infections are infections that occur more often and are more severe in people with weakened immune systems than in people with healthy immune systems 1. People with weakened immune systems include people living with HIV or people receiving chemotherapy. People are at greatest risk for opportunistic infections when their CD4 count falls below 200, but you can get some opportunistic infections when your CD4 count is below 500.

Opportunistic infections are caused by a variety of germs (viruses, bacteria, fungi, and parasites). Opportunistic infection-causing germs can spread in the air; in saliva, semen, blood, urine, or feces (poop); or in contaminated food and water. Here are examples of common HIV-related opportunistic infections.

Here are examples of common HIV-related opportunistic infections:

  • Pneumocystis carinii pneumonia
  • Candidiasis (or thrush)—a fungal infection of the mouth, bronchi, trachea, lungs, esophagus, or vagina
  • Herpes simplex virus 1 (HSV-1) infection—a viral infection that can cause lesions (sores) on the lips, mouth, and face
  • Herpes zoster
  • Mycobacterium avium complex infection
  • Cytomegalovirus disease
  • Cerebral toxoplasmosis
  • Cryptococcosis
  • Salmonella infection—a bacterial infection that affects the intestines (the gut)
  • Toxoplasmosis—a parasitic infection that can affect the brain

Opportunistic infections are less common now than they were in the early days of HIV and AIDS because better treatments reduce the amount of HIV in a person’s body and keep a person’s immune system stronger. However, many people with HIV still develop opportunistic infections because they did not know they had HIV for many years after they were infected. Others people who know they have HIV can get opportunistic infections because they are not taking antiretroviral treatment (ART); they are on ART, but it is failing and the virus has weakened their immune system; or they have AIDS but are not taking medication to prevent opportunistic infections.

Despite the availability of multiple safe, effective, and simple antiretroviral treatment (ART) regimens, and a corresponding steady decline in the incidence of opportunistic infections 2, the Centers for Disease Control and Prevention (CDC) estimates that more than 40% of Americans with HIV are not effectively virally suppressed 3. As a result, opportunistic infections continue to cause preventable morbidity and mortality in the United States 4.

Achieving and maintaining durable viral suppression in all people with HIV, and thus preventing or substantially reducing the incidence of HIV related opportunistic infections, remains challenging for three main reasons:

  • Not all HIV infections are diagnosed, and once diagnosed many persons have already experienced substantial immunosuppression. CDC estimates that in 2015, 15% of the people with HIV in the United States were unaware of their infections 5. Among those with diagnosed HIV, more than 50% had had HIV for more than 3 years20 and approximately 20% had a CD4 T lymphocyte (CD4) cell count <200 cells/mm3 (or <14%) at the time of diagnosis 6.
  • Not all persons with diagnosed HIV receive timely continuous HIV care or are prescribed ART. CDC estimates that in 2015, 16% of persons with newly diagnosed HIV had not been linked to care within 3 months and among persons living with HIV only 57% were adequately engaged in continuous care 7
  • Not all persons treated for HIV achieve durable viral suppression. CDC estimates that in 2014, only 49% of diagnosed patients were effectively linked to care and had durable viral suppression 8. Causes for the suboptimal response to treatment include poor adherence, unfavorable pharmacokinetics, or unexplained biologic factors 9.

Thus, some persons with HIV infection will continue to present with an opportunistic infection as the sentinel event leading to a diagnosis of HIV infection or present with an opportunistic infection as a complication of unsuccessful viral suppression.

Durable viral suppression eliminates most but not all opportunistic infections. Tuberculosis, pneumococcal disease, and dermatomal zoster are examples of infectious diseases that occur at higher incidence in persons with HIV regardless of CD4 count. The likelihood of each of these opportunistic infections occurring does vary inversely with the CD4 count 10.

When certain opportunistic infections occur— most notably tuberculosis and syphilis—they can increase plasma viral load 11, which both accelerates HIV progression and increases the risk of HIV transmission.

 

 

 

 

Staying in care and getting your lab tests done is one of the most important things you can do to prevent opportunistic infections. This will allow your provider to know when you might be at risk for opportunistic infections and work with you to prevent them. Some opportunistic infections can be prevented by taking additional medication that is used to prevent that opportunistic infection.

If you do develop an opportunistic infection, there are treatments available, such as antibiotics or antifungal drugs. Having an opportunistic infection may be a very serious medical situation and its treatment can be challenging. The best way to prevent opportunistic infections is to reduce your risk by staying in care, taking antiretroviral treatment (ART) every day, and keeping your viral load undetectable or very low so that your immune system can stay strong.

List of opportunistic infections

Following is a list of the most common opportunistic infections for people living in the United States 12.

Candidiasis of bronchi, trachea, esophagus, or lungsThis illness is caused by infection with a common (and usually harmless) type of fungus called Candida. Candidiasis, or infection with Candida, can affect the skin, nails, and mucous membranes throughout the body. Persons with HIV infection often have trouble with Candida, especially in the mouth and vagina. However, candidiasis is only considered an OI when it infects the esophagus (swallowing tube) or lower respiratory tract, such as the trachea and bronchi (breathing tube), or deeper lung tissue.
Invasive cervical cancerThis is a cancer that starts within the cervix, which is the lower part of the uterus at the top of the vagina, and then spreads (becomes invasive) to other parts of the body. This cancer can be prevented by having your care provider perform regular examinations of the cervix
CoccidioidomycosisThis illness is caused by the fungus Coccidioides immitis. It most commonly acquired by inhaling fungal spores, which can lead to a pneumonia that is sometimes called desert fever, San Joaquin Valley fever, or valley fever. The disease is especially common in hot, dry regions of the southwestern United States, Central America, and South America.
CryptococcosisThis illness is caused by infection with the fungus Cryptococcus neoformans. The fungus typically enters the body through the lungs and can cause pneumonia. It can also spread to the brain, causing swelling of the brain. It can infect any part of the body, but (after the brain and lungs) infections of skin, bones, or urinary tract are most common.
Cryptosporidiosis, chronic intestinal (greater than one month’s duration)This diarrheal disease is caused by the protozoan parasite Cryptosporidium. Symptoms include abdominal cramps and severe, chronic, watery diarrhea.
Cytomegalovirus diseases (particularly retinitis) (CMV)This virus can infect multiple parts of the body and cause pneumonia, gastroenteritis (especially abdominal pain caused by infection of the colon), encephalitis (infection) of the brain, and sight-threatening retinitis (infection of the retina at the back of eye). People with CMV retinitis have difficulty with vision that worsens over? time. CMV retinitis is a medical emergency because it can cause blindness if not treated promptly.
Encephalopathy, HIV-relatedThis brain disorder is a result of HIV infection. It can occur as part of acute HIV infection or can result from chronic HIV infection. Its exact cause is unknown but it is thought to be related to infection of the brain with HIV and the resulting inflammation.
Herpes simplex (HSV): chronic ulcer(s) (greater than one month’s duration); or bronchitis, pneumonitis, or esophagitisHerpes simplex virus (HSV) is a very common virus that for most people never causes any major problems. HSV is usually acquired sexually or from an infected mother during birth. In most people with healthy immune systems, HSV is usually latent (inactive). However, stress, trauma, other infections, or suppression of the immune system, (such as by HIV), can reactivate the latent virus and symptoms can return. HSV can cause painful cold sores (sometime called fever blisters) in or around the mouth, or painful ulcers on or around the genitals or anus. In people with severely damaged immune systems, HSV can also cause infection of the bronchus (breathing tube), pneumonia (infection of the lungs), and esophagitis (infection of the esophagus, or swallowing tube).
HistoplasmosisThis illness is caused by the fungus Histoplasma capsulatum. Histoplasma most often infects the lungs and produces symptoms that are similar to those of influenza or pneumonia. People with severely damaged immune systems can get a very serious form of the disease called progressive disseminated histoplasmosis. This form of histoplasmosis can last a long time and involves organs other than the lungs.
Isosporiasis, chronic intestinal (greater than one month’s duration)This infection is caused by the parasite Isospora belli, which can enter the body through contaminated food or water. Symptoms include diarrhea, fever, headache, abdominal pain, vomiting, and weight loss.
Kaposi’s sarcoma (KS)This cancer, also known as KS, is caused by a virus called Kaposi’s sarcoma herpesvirus (KSHV) or human herpesvirus 8 (HHV-8). KS causes small blood vessels, called capillaries, to grow abnormally. Because capillaries are located throughout the body, KS can occur anywhere. KS appears as firm pink or purple spots on the skin that can be raised or flat. KS can be life-threatening when it affects organs inside the body, such the lung, lymph nodes, or intestines.
Lymphoma, multiple formsLymphoma refers to cancer of the lymph nodes and other lymphoid tissues in the body. There are many different kinds of lymphomas. Some types, such as non-Hodgkin lymphoma and Hodgkin lymphoma, are associated with HIV infection.
Tuberculosis (TB)Tuberculosis (TB) infection is caused by the bacteria Mycobacterium tuberculosis. TB can be spread through the air when a person with active TB coughs, sneezes, or speaks. Breathing in the bacteria can lead to infection in the lungs. Symptoms of TB in the lungs include cough, tiredness, weight loss, fever, and night sweats. Although the disease usually occurs in the lungs, it may also affect other parts of the body, most often the larynx, lymph nodes, brain, kidneys, or bones.
Mycobacterium avium complex (MAC) or Mycobacterium kansasii, disseminated or extrapulmonary. Other Mycobacterium, disseminated or extrapulmonary.MAC is caused by infection with different types of mycobacterium: Mycobacterium avium, Mycobacterium intracellulare, or Mycobacterium kansasii. These mycobacteria live in our environment, including in soil and dust particles. They rarely cause problems for persons with healthy immune systems. In people with severely damaged immune systems, infections with these bacteria spread throughout the body and can be life-threatening.
Pneumocystis carinii pneumonia (PCP)This lung infection, also called PCP, is caused by a fungus, which used to be called Pneumocystis carinii, but now is named Pneumocystis jirovecii. PCP occurs in people with weakened immune systems, including people with HIV. The first signs of infection are difficulty breathing, high fever, and dry cough.
Pneumonia, recurrentPneumonia is an infection in one or both of the lungs. Many germs, including bacteria, viruses, and fungi can cause pneumonia, with symptoms such as a cough (with mucous), fever, chills, and trouble breathing. In people with immune systems severely damaged by HIV, one of the most common and life-threatening causes of pneumonia is infection with the bacteria Streptococcus pneumoniae, also called Pneumococcus. There are now effective vaccines that can prevent infection with Streptococcus pneumoniae and all persons with HIV infection should be vaccinated.
Progressive multifocal leukoencephalopathyThis rare brain and spinal cord disease is caused by the JC (John Cunningham) virus. It is seen almost exclusively in persons whose immune systems have been severely damaged by HIV. Symptoms may include loss of muscle control, paralysis, blindness, speech problems, and an altered mental state. This disease often progresses rapidly and may be fatal.
Salmonella septicemia, recurrentSalmonella are a kind of bacteria that typically enter the body through ingestion of contaminated food or water. Infection with salmonella (called salmonellosis) can affect anyone and usually causes a self-limited illness with nausea, vomiting, and diarrhea. Salmonella septicemia is a severe form of infection in which the bacteria circulate through the whole body and exceeds the immune system’s ability to control it.
Toxoplasmosis of brainThis infection, often called toxo, is caused by the parasite Toxoplasma gondii. The parasite is carried by warm-blooded animals including cats, rodents, and birds and is excreted by these animals in their feces. Humans can become infected with it by inhaling dust or eating food contaminated with the parasite. Toxoplasma can also occur in commercial meats, especially red meats and pork, but rarely poultry. Infection with toxo can occur in the lungs, retina of the eye, heart, pancreas, liver, colon, testes, and brain. Although cats can transmit toxoplasmosis, litter boxes can be changed safely by wearing gloves and washing hands thoroughly with soap and water afterwards. All raw red meats that have not been frozen for at least 24 hours should be cooked through to an internal temperature of at least 150oF.
Wasting syndrome due to HIVWasting is defined as the involuntary loss of more than 10% of one’s body weight while having experienced diarrhea or weakness and fever for more than 30 days. Wasting refers to the loss of muscle mass, although part of the weight loss may also be due to loss of fat.

Why do people with HIV get opportunistic infections?

Once a person is infected with HIV, the virus begins to multiply and to damage the immune system. A weakened immune system makes it harder for the body to fight off HIV-related opportunistic infections.

HIV medicines prevent HIV from damaging the immune system. But if a person with HIV does not take HIV medicines, HIV infection can gradually destroy the immune system and advance to AIDS. Many opportunistic infections, for example, certain forms of pneumonia and tuberculosis (TB), are considered AIDS-defining conditions. AIDS-defining conditions are infections and cancers that are life-threatening in people with HIV.

Are opportunistic infections common in people with HIV?

Before HIV medicines were available to treat HIV infection, opportunistic infections were the main cause of illness and death in people with HIV. HIV medicines are now widely used in the United States so fewer people with HIV get opportunistic infections. By preventing HIV from damaging the immune system, HIV medicines reduce the risk of opportunistic infections.

However, opportunistic infections are still a problem for many people with HIV. Some people with HIV get opportunistic infections for the following reasons:

  • About 15% of people who have HIV don’t know that they are infected. An opportunistic infection may be the first sign that they have HIV.
  • Some people who know they have HIV aren’t getting treatment with HIV medicines. Without HIV treatment, they are more likely to get an opportunistic infection.
  • Some people may be taking HIV medicines, but the medicines aren’t controlling their HIV. Poorly controlled HIV can be due to many factors, including lack of health care, poor medication adherence, or incomplete absorption of HIV medicines. People with poorly controlled HIV have an increased risk of getting an opportunistic infection.

What can people with HIV do to prevent getting an opportunistic infection?

For people with HIV, the best protection against opportunistic infections is to take HIV medicines every day.

People living with HIV can also take the following steps to reduce their risk of getting an opportunistic infection.

Avoid contact with the germs that can cause opportunistic infections.

The germs that can cause opportunistic infections can spread in the feces of people and animals. To prevent opportunistic infections, don’t touch animal feces. Wash your hands with warm, soapy water after touching anything soiled with human feces, for example, a dirty diaper. Ask your health care provider about other ways to avoid the germs that can cause opportunistic infections.

In addition to taking HIV medications to keep your immune system strong, there are other steps you can take to prevent getting an opportunistic infection:

  • Prevent exposure to other sexually transmitted infections.
  • Don’t share drug injection equipment. Blood with hepatitis C in it can remain in syringes and needles after use and the infection can be transmitted to the next user.
  • Get vaccinated – your doctor can tell you what vaccines you need. If he or she doesn’t, you should ask.
  • Understand what germs you are exposed to (such as tuberculosis or germs found in the stools, saliva, or on the skin of animals) and limit your exposure to them.
  • Don’t consume certain foods, including undercooked eggs, unpasteurized (raw) milk and cheeses, unpasteurized fruit juices, or raw seed sprouts.
  • Don’t drink untreated water such as water directly from lakes or rivers. Tap water in foreign countries is also often not safe. Use bottled water or water filters.
  • Ask your doctor to review with you the other things you do at work, at home, and on vacation to make sure you aren’t exposed to an opportunistic infection.

Be careful about what you eat and drink.

Food and water can be contaminated with opportunistic infection-causing germs. To be safe, don’t eat or drink the following foods:

  • Raw or undercooked eggs, for example, in homemade mayonnaise or uncooked cookie dough
  • Raw or undercooked poultry, meat, and seafood (especially raw shellfish)
  • Unpasteurized milk, cheeses, and fruit juices
  • Raw seed sprouts, such as alfalfa sprouts or mung bean sprouts

Only drink tap water, filtered water, or bottled water. Don’t drink water directly from a lake or river.

Can opportunistic infections be treated?

There are many medicines to treat HIV-related opportunistic infections, including antiviral, antibiotic, and antifungal drugs. The type of medicine used depends on the opportunistic infection.

Once an opportunistic infection is successfully treated, a person may continue to use the same medicine or an additional medicine to prevent the opportunistic infection from reoccurring (coming back).

HIV opportunistic infections guidelines

Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. You can get a copy of the latest guidelines from https://aidsinfo.nih.gov/guidelines

Table 1. Prophylaxis to Prevent First Episode of Opportunistic Disease

Opportunistic InfectionsIndicationPreferredAlternative
Pneumocystis pneumonia (PCP)
  • CD4 count <200 cells/ mm3 (AI), or
  • CD4 <14% (BII), or
  • CD4 count >200 but <250 cells/mm3 if monitoring CD4 cell count every 3 months is not possible (BII)

Note: Patients who are receiving pyrimethamine/ sulfadiazine for treatment or suppression of toxoplasmosis do not require additional PCP prophylaxis (AII).

  • TMP-SMXa 1 double-strength (DS) PO daily (AI), or
  • TMP-SMXa 1 single-strength (SS) daily (AI)
  • TMP-SMXa 1 DS PO three times weekly (BI), or
  • Dapsoneb 100 mg PO daily or 50 mg PO BID (BI), or
  • Dapsoneb 50 mg PO daily + (pyrimethaminec 50 mg + leucovorin 25 mg) PO weekly (BI), or
  • (Dapsoneb 200 mg + pyrimethaminec 75 mg + leucovorin 25 mg) PO weekly (BI); or
  • Aerosolized pentamidine 300 mg via Respigard II™ nebulizer every month (BI), or
  • Atovaquone 1500 mg PO daily (BI), or
  • (Atovaquone 1500 mg + pyrimethaminec 25 mg + leucovorin 10 mg) PO daily (CIII)
Toxoplasma gondii encephalitis
  • Toxoplasma IgG-positive patients with CD4 count <100 cells/µL (AII)

Note: All regimens recommended for primary prophylaxis against toxoplasmosis are also effective as PCP prophylaxis

TMP-SMXa 1 DS PO daily (AII)
  • TMP-SMXa 1 DS PO three times weekly (BIII), or
  • TMP-SMXa 1 SS PO daily (BIII), or
  • Dapsoneb 50 mg PO daily + (pyrimethaminec 50 mg + leucovorin 25 mg) PO weekly (BI), or
  • (Dapsoneb 200 mg + pyrimethaminec 75 mg + leucovorin 25 mg) PO weekly (BI); or
  • Atovaquone 1500 mg PO daily (CIII) ; or
  • (Atovaquone 1500 mg + pyrimethaminec 25 mg + leucovorin 10 mg) PO daily (CIII)
Mycobacterium tuberculosis infection (TB) (i.e., treatment of latent TB infection [LTBI])
  • (+) screening test for LTBId, with no evidence of active TB, and no prior treatment for active TB or LTBI (AI), or
  • Close contact with a person with infectious TB, with no evidence of active TB, regardless of screening test results (AII).
  • (INH 300 mg + pyridoxine 25-50 mg) PO daily x 9 months (AII), or
  • INH 900 mg PO BIW (by DOT) + pyridoxine 25-50 mg PO daily x 9 months (BII).
  • Rifampin 600 mg PO daily x 4 months (BIII), or
  • Rifabutin (dose adjusted based on concomitant ART)e x 4 months (BIII), or
  • [Rifapentine (see dose below) PO + INH 900 mg PO + pyridoxine 50 mg PO] once weekly x 12 weeks

    rifapentine dose

    • 32.1 to 49.9 kg: 750 mg
    • 50 mg: 900 mg

Rifapentine only recommended  for patients receiving raltegravir or efavirenz-based ART regimen

For persons exposed to drug-resistant TB, select anti-TB drugs after consultation with experts or public health authorities (AII).

Disseminated Mycobacterium avium complex (MAC) diseaseCD4 count <50 cells/µL—after ruling out active disseminated MAC disease based on clinical assessment (AI).
  • Azithromycin 1200 mg PO once weekly (AI), or
  • Clarithromycin 500 mg PO BID (AI), or
  • Azithromycin 600 mg PO twice weekly (BIII)
Rifabutin (dose adjusted based on concomitant ART)e (BI); rule out active TB before starting rifabutin.
Streptococcus pneumoniae infectionFor individuals who have not received any pneumococcal vaccine, regardless of CD4 count, followed by:

  • if CD4 count ≥200 cells/µL
  • if CD4 count <200 cells/µL
PCV13 0.5 mL IM x 1 (AI).

PPV23 0.5 mL IM at least 8 weeks after the PCV13 vaccine (AII).

PPV23 can be offered at least 8 weeks after receiving PCV13 (CIII) or can wait until CD4 count increased to ≥200 cells/µL (BIII).

PPV23 0.5 mL IM x 1 (BII)
For individuals who have previously received PPV23One dose of PCV13 should be given at least 1 year after the last receipt of PPV23 (AII).
Re-vaccination

  • If age 19–64 years and ≥5 years since the first PPV23 dose
  • If age ≥65 years, and if ≥5 years since the previous PPV23 dose
  • PPV23 0.5 mL IM or SQ x 1 (BIII)
  • PPV23 0.5 mL IM or SQ x 1 (BIII)
Influenza A and B virus infectionAll HIV-infected patients (AIII)Inactivated influenza vaccine annually (per recommendation for the season) (AIII)

Live-attenuated influenza vaccine is contraindicated in HIV-infected patients (AIII).

Syphilis
  • For individuals exposed to a sex partner with a diagnosis of primary, secondary, or early latent syphilis within past 90 days (AII), or
  • For individuals exposed to a sex partner >90 days before syphilis diagnosis in the partner, if serologic test results are not available immediately and the opportunity for follow-up is uncertain (AIII)
Benzathine penicillin G 2.4 million units IM for 1 dose (AII)For penicillin-allergic patients:

  • Doxycycline 100 mg PO BID for 14 days (BII), or
  • Ceftriaxone 1 g IM or IV daily for 8–10 days (BII), or
  • Azithromycin 2 g PO for 1 dose (BII) – not recommended for MSM or pregnant women (AII)
Histoplasma capsulatum infectionCD4 count ≤150 cells/µL and at high risk because of occupational exposure or live in a community with a hyperendemic rate of histoplasmosis (>10 cases/100 patient-years) (BI)Itraconazole 200 mg PO daily (BI)
Coccidioido-mycosisA new positive IgM or IgG serologic test in patients who live in a disease-endemic area and with CD4 count <250 cells/µL (BIII)Fluconazole 400 mg PO daily (BIII)
Varicella-zoster virus (VZV) infectionPre-exposure prevention:
Patients with CD4 counts ≥200 cells/µL who have not been vaccinated, have no history of varicella or herpes zoster, or who are seronegative for VZV (CIII)

Note: Routine VZV serologic testing in HIV-infected adults and adolescents is not recommended.

Post-exposure prevention: (AIII)
Close contact with a person with chickenpox or herpes zoster; and is susceptible (i.e., no history of vaccination or of either condition, or known to be VZV seronegative)

Pre-exposure prevention:
Primary varicella vaccination (Varivax™), 2 doses (0.5 mL SQ each) administered 3 months apart (CIII).

If vaccination results in disease because of vaccine virus, treatment with acyclovir is recommended (AIII).

Post-exposure prevention:
Varicella-zoster immune globulin (VariZIG™) 125 international units per 10 kg (maximum 625 international units) IM, administered as soon as possible and within 10 days after exposure (AIII)

Note: VariZIG is exclusively distributed by FFF Enterprises at 800-843-7477.

Individuals receiving monthly high-dose IVIG (>400 mg/kg) are likely to be protected if the last dose of IVIG was administered <3 weeks before exposure.

Pre-exposure prevention:
VZV-susceptible household contacts of susceptible HIV-infected persons should be vaccinated to prevent potential transmission of VZV to their HIV-infected contacts (BIII).

Alternative post-exposure prevention:

  • Acyclovir 800 mg PO 5 x/day for 5–7 days (BIII), or
  • Valacyclovir 1 g PO TID for 5–7 days (BIII)

These alternatives have not been studied in the HIV population.

If antiviral therapy is used, varicella vaccines should not be given until at least 72 hours after the last dose of the antiviral drug.

Human Papillomavirus (HPV) infectionFemales and males aged 13–26 years (BIII)
  • HPV recombinant vaccine 9 valent (Types 6,11,16,18,31,33,45,52,58) 0.5mL IM at 0, 1–2, and 6 months (BIII)
For patients who have completed a vaccination series with the recombinant bivalent or quadrivalent vaccine, providers may consider additional vaccination with recombinant 9-valent vaccine, but there are no data to define who might benefit or how cost effective this approach might be (CIII).
Hepatitis A virus (HAV) infectionHAV-susceptible patients with chronic liver disease, or who are injection-drug users, or MSM (AII).Hepatitis A vaccine 1 mL IM x 2 doses at 0 and 6–12 months (AII).

IgG antibody response should be assessed 1 month after vaccination; non-responders should be revaccinated when CD4 count >200 cells/µL (BIII).

For patients susceptible to both HAV and hepatitis B virus (HBV) infection (see below):
Combined HAV and HBV vaccine (Twinrix®), 1 mL IM as a 3-dose (0, 1, and 6 months) or 4-dose series (days 0, 7, 21 to 30, and 12 months) (AII)
Hepatitis B virus (HBV) infection
  • Patients without chronic HBV or without immunity to HBV (i.e.,with anti-HBs <10 IU/mL) (AII)
  • Patients with isolated anti-HBc: vaccinate with 1 standard dose of HBV vaccine, check anti-HBs 1-2 months after, if >100 IU, no further vaccination needed. If titer is <100IU, vaccinate with full series (BII)
  • Early vaccination is recommended before CD4 count falls below 350 cells/µL (AII).
  • However, in patients with low CD4 cell counts, vaccination should not be deferred until CD4 count reaches >350 cells/µL, because some patients with CD4 counts <200 cells/µL do respond to vaccination (AII).
  • HBV vaccine IM (Engerix-B 20 µg/mL or Recombivax HB 10 µg/mL), 0, 1, and 6 months (AII), or
  • HBV vaccine IM (Engerix-B 40 µg/mL or Recombivax HB 20 µg/mL), 0, 1, 2 and 6 months (BI),
  • Combined HAV and HBV vaccine (Twinrix®), 1 mL IM as a 3-dose (0, 1, and 6 months) or 4-dose series (days 0, 7, 21 to 30, and 12 months) (AII)

Anti-HBs should be obtained 1-2 months after completion of the vaccine series. Patients with anti-HBs <10 IU/mL are considered non-responders, and should be revaccinated with another 3-dose series (BIII).

Some experts recommend vaccinating with 4-doses of double dose of either HBV vaccine (BI).
Vaccine Non-Responders:

  • Anti-HBs <10 international units/mL 1 month after vaccination series
  • For patients with low CD4 counts at time of first vaccine series, some experts might delay revaccination until after a sustained increase in CD4 count with ART (CIII).
Re-vaccinate with a second vaccine series (BIII)
  • HBV vaccine IM (Engerix-B 40 µg/mL or Recombivax HB 20 µg/mL), 0, 1, 2 and 6 months (BI).
MalariaTravel to disease-endemic areaRecommendations are the same for HIV-infected and HIV-uninfected patients. Recommendations are based on region of travel, malaria risks, and drug susceptibility in the region. Refer to the following website for the most recent recommendations based on region and drug susceptibility:
http://www.cdc.gov/malaria/.
PenicilliosisPatients with CD4 cell counts <100 cells/µL who live or stay for a long period in rural areas in northern Thailand, Vietnam, or Southern China (BI)Itraconazole 200 mg once daily (BI)Fluconazole 400 mg PO once weekly (BII)
Key to Acronyms: anti-HBc = hepatitis B core antibody; anti-HBs = hepatitis B surface antibody; ART = antiretroviral therapy; BID = twice daily; BIW = twice a week; CD4 = CD4 T lymphocyte cell; DOT = directly observed therapy; DS = double strength; HAV = hepatitis A virus; HBV = hepatitis B virus; HPV = human papillomavirus; IgG = immunoglobulin G; IgM = immunoglobulin M; IM = intramuscular; INH = isoniazid; IV= intravenously; IVIG = intravenous immunoglobulin; LTBI = latent tuberculosis infection; MAC = Mycobacterium avium complex; PCP = Pneumocystis pneumonia; PCV13 = 13-valent pneumococcal conjugate vaccine; PO = orally; PPV23 = 23-valent pneumococcal polysaccharides vaccine; SQ = subcutaneous; SS = single strength; TB = tuberculosis; TMP-SMX = Trimethoprim-sulfamethoxazole; VZV = varicella zoster virus

a TMP-SMX DS once daily also confers protection against toxoplasmosis and many respiratory bacterial infections; lower dose also likely confers protection
b Patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) before administration of dapsone or primaquine. Alternative agent should be used in patients found to have G6PD deficiency
c Screening tests for LTBI include tuberculin skin test (TST) or interferon-gamma release assays (IGRA)
d Refer to Drug Interactions section in the Adult and Adolescent ARV Guidelines for dosing recommendation

Footnotes:

Evidence Rating

Strength of Recommendation:

  • A: Strong recommendation for the statement
  • B: Moderate recommendation for the statement
  • C: Optional recommendation for the statement

Quality of Evidence for the Recommendation:

  • I: One or more randomized trials with clinical outcomes and/or validated laboratory endpoints
  • II: One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes
  • III: Expert opinion

In cases where there are no data for the prevention or treatment of an opportunistic infection based on studies conducted in HIV-infected populations, but data derived from HIV-uninfected patients exist that can plausibly guide management decisions for patients with HIV/AIDS, the data will be rated as III but will be assigned recommendations of A, B, C depending on the strength of recommendation.

[Source 13]

Table 2. Treatment of AIDS-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)

Opportunistic InfectionPreferred TherapyAlternative TherapyOther Comments
Pneumocystis Pneumonia (PCP)Patients who develop PCP despite TMP-SMX prophylaxis can usually be treated with standard doses of TMP-SMX (BIII).

Duration of PCP treatment: 21 days (AII)

For Moderate-to-Severe PCP:

  • TMP-SMX: [TMP 15–20 mg and SMX 75–100 mg]/kg/day IV given q6h or q8h (AI), may switch to PO after clinical improvement (AI)

For Mild-to-Moderate PCP:

  • TMP-SMX: [TMP 15–20 mg and SMX 75–100 mg]/kg/day, given PO in 3 divided doses (AI), or
  • TMP-SMX: (160 mg/800 mg or DS) 2 tablets PO TID (AI)

Secondary Prophylaxis, after completion of PCP treatment:

  • TMP-SMX DS: 1 tablet PO daily (AI), or
  • TMP-SMX (80 mg/400 mg or SS): 1 tablet PO daily (AI)
For Moderate-to-Severe PCP:

  • Pentamidine 4 mg/kg IV daily infused over ≥60 minutes (AI); can reduce dose to 3 mg/kg IV daily because of toxicities (BI), or
  • Primaquine 30 mg (base) PO daily + (clindamycin 600 mg q6h IV or 900 mg IV q8h) or (clindamycin 450 mg PO q6h or 600 mg PO q8h) (AI)

For Mild-to-Moderate PCP:

  • Dapsone 100 mg PO daily + TMP 5 mg/kg PO TID (BI), or
  • Primaquine 30 mg (base) PO daily + (clindamycin 450 mg PO q6h or 600 mg PO q8h) (BI), or
  • Atovaquone 750 mg PO BID with food (BI)

Secondary Prophylaxis, after completion of PCP treatment:

  • TMP-SMX DS: 1 tablet PO three times weekly (BI), or
  • Dapsone 100 mg PO daily (BI), or
  • Dapsone 50 mg PO daily + (pyrimethaminea 50 mg + leucovorin 25 mg) PO weekly (BI), or
  • (Dapsone 200 mg + pyrimethaminea 75 mg + leucovorin 25 mg) PO weekly (BI), or
  • Aerosolized pentamidine 300 mg monthly via Respirgard II™ nebulizer (BI), or
  • Atovaquone 1500 mg PO daily (BI), or
  • (Atovaquone 1500 mg + pyrimethaminea 25 mg + leucovorin 10 mg) PO daily (CIII)
Indications for Adjunctive Corticosteroids (AI):

  • PaO2 <70 mm Hg at room air, or
  • Alveolar-arterial O2 gradient >35 mm Hg

Prednisone Doses (Beginning as Early as Possible and Within 72 Hours of PCP Therapy) (AI):

  • Days 1–5: 40 mg PO BID
  • Days 6–10: 40 mg PO daily
  • Days 11–21: 20 mg PO daily

IV methylprednisolone can be administered as 75% of prednisone dose.

Benefit of corticosteroid if started after 72 hours of treatment is unknown, but some clinicians will use it for moderate-to-severe PCP (BIII).

Whenever possible, patients should be tested for G6PD before use of dapsone or primaquine. Alternative therapy should be used in patients found to have G6PD deficiency.

Patients who are receiving pyrimethaminea/sulfadiazine for treatment or suppression of toxoplasmosis do not require additional PCP prophylaxis (AII).

If TMP-SMX is discontinued because of a mild adverse reaction, re-institution should be considered after the reaction resolves (AII). The dose can be increased gradually (desensitization) (BI), reduced, or the frequency modified (CIII).

TMP-SMX should be permanently discontinued in patients with possible or definite Stevens-Johnson Syndrome or toxic epidermal necrosis (AII).

Toxoplasma gondii EncephalitisTreatment of Acute Infection (AI):

  • Pyrimethaminea 200 mg PO 1 time, followed by weight-based therapy:
    • If <60 kg, pyrimethaminea 50 mg PO once daily + sulfadiazine 1000 mg PO q6h + leucovorin 10–25 mg PO once daily
    • If ≥60 kg, pyrimethaminea 75 mg PO once daily + sulfadiazine 1500 mg PO q6h + leucovorin 10–25 mg PO once daily
  • Leucovorin dose can be increased to 50 mg daily or BID.

Duration for Acute Therapy:

  • At least 6 weeks (BII); longer duration if clinical or radiologic disease is extensive or response is incomplete at 6 weeks
  • After completion of acute therapy, all patients should be initated on chronic maintenance therapy

Chronic Maintenance Therapy:

  • Pyrimethaminea 25–50 mg PO daily + sulfadiazine 2000–4000 mg PO daily (in 2–4 divided doses) + leucovorin 10–25 mg PO daily (AI)
Treatment of Acute Infection:

  • Pyrimethaminea (leucovorin)* + clindamycin 600 mg IV or PO q6h (AI), or
  • TMP-SMX (TMP 5 mg/kg and SMX 25 mg/kg ) IV or PO BID (BI), or
  • Atovaquone 1500 mg PO BID with food + pyrimethaminea (leucovorin)* (BII), or
  • Atovaquone 1500 mg PO BID with food + sulfadiazine 1000–1500 mg PO q6h (weight-based dosing, as in preferred therapy) (BII), or
  • Atovaquone 1500 mg PO BID with food (BII),

Chronic Maintenance Therapy:

  • Clindamycin 600 mg PO q8h + (pyrimethaminea 25–50 mg + leucovorin 10–25 mg) PO daily (BI), or
  • TMP-SMX DS 1 tablet BID (BII), or
  • TMP-SMX DS I tablet once daily (BII); or
  • Atovaquone 750–1500 mg PO BID + (pyrimethaminea 25 mg + leucovorin 10 mg) PO daily (BII), or
  • Atovaquone 750–1500 mg PO BID + sulfadiazine 2000–4000 mg PO daily (in 2–4 divided doses) (BII), or
  • Atovaquone 750–1500 mg PO BID with food (BII)

*Pyrimethaminea and leucovorin doses are the same as for preferred therapy.

Refer to http://www.daraprimdirect.com for information regarding how to access pyrimethamine

If pyrimethamine is unavailable or there is a delay in obtaining it, TMP-SMX should be utilized in place of pyrimethamine-sulfadiazine (BI).

For patients with a history of sulfa allergy, sulfa desensitization should be attempted using one of several published strategies (BI).

Atovaquone should be administered until therapeutic doses of TMP-SMX are achieved (CIII).

Adjunctive corticosteroids (e.g., dexamethasone) should only be administered when clinically indicated to treat mass effect associated with focal lesions or associated edema (BIII); discontinue as soon as clinically feasible.

Anticonvulsants should be administered to patients with a history of seizures (AIII) and continued through acute treatment, but should not be used as seizure prophylaxis (AIII).

If clindamycin is used in place of sulfadiazine, additional therapy must be added to prevent PCP (AII).

Cryptosporidiosis
  • Initiate or optimize ART for immune restoration to CD4 count >100 cells/µL (AII), and
  • Aggressive oral or IV rehydration and replacement of electrolyte loss (AIII)and
  • Symptomatic treatment of diarrhea with anti-motility agents (AIII).
No therapy has been shown to be effective without ART. Trial of these agents may be used in conjunction with, but not instead of, ART:

  • Nitazoxanide 500–1000 mg PO BID for 14 days (CIII), or
  • Paromomycin 500 mg PO QID for 14–21 days (CIII)
  • With optimized ART, symptomatic treatment and rehydration and electrolyte replacement
Tincture of opium may be more effective than loperamide in management of diarrhea (CIII).
MicrosporidiosisFor GI Infections Caused by Enterocytozoon bienuesi:

  • Initiate or optimize ART as immune restoration to CD4 count >100 cells/µL (AII); plus
  • Manage severe dehydration, malnutrition, and wasting by fluid support (AII) and nutritional supplement (AIII)

For Intestinal and Disseminated (Not Ocular) Infections Caused by Microsporidia Other Than E. bienuesi and Vittaforma corneae:

  • Albendazole 400 mg PO BID (AII), continue until CD4 count >200 cells/µL for >6 months after initiation of ART (BIII)

For Ocular Infection:

  • Topical fumagillin bicylohexyl-ammonium (Fumidil B) eye drops: 3 mg/mL in saline (fumagillin 70 µg/mL) —2 drops q2h for 4 days, then 2 drops QID (investigational use only in United States) (BII) + albendazole 400 mg PO BID, for management of systemic infection (BIII)
  • Therapy should be continued until resolution of ocular symptoms and CD4 count increase to >200 cells/ µL for >6 months in response to ART (CIII).
For GI Infections Caused by E. bienuesi:

  • Fumagillin 60 mg/day (BII) and TNP-470 (a synthetic analog of fumagillin) (BIII) may be effective, but neither is available in the United States.
  • Nitazoxanide (1000 mg BID) may have some effect but response may be minimal in patients with low CD4 cell counts (CIII).

For Disseminated Disease Attributed to Trachipleistophora or Anncaliia:

  • Itraconazole 400 mg PO daily + albendazole 400 mg PO BID (CIII)
Anti-motility agents can be used for diarrhea control if required (BIII).
Mycobacterium tuberculosis (TB) DiseaseAfter collecting specimen for culture and molecular diagnostic tests, empiric TB treatment should be started in individuals with clinical and radiographic presentation suggestive of TB (AIII).

Refer to Table 3 for dosing recommendations.

Initial Phase (2 Months, Given Daily, 5–7 Times/Week by DOT) (AI):

  • INH + [RIF or RFB] + PZA + EMB (AI),

Continuation Phase:

  • INH + (RIF or RFB) daily (5–7 times/week)

Total Duration of Therapy (For Drug-Susceptible TB):

  • Pulmonary, drug-susceptible TB: 6 months (BII)
  • Pulmonary TB and culture-positive after 2 months of TB treatment: 9 months (BII)
  • Extra-pulmonary TB w/CNS infection: 9–12 months (BII);
  • Extra-pulmonary TB w/bone or joint involvement: 6 to 9 months (BII);
  • Extra-pulmonary TB in other sites: 6 months (BII)

Total duration of therapy should be based on number of doses received, not on calendar time

Treatment for Drug Resistant TB

Resistant to INH:

  • (RIF or RFB) + EMB + PZA + (moxifloxacin or levofloxacin) for 2 months (BII); followed by (RIF or RFB) + EMB + (moxifloxacin or levofloxacin) for 7 months (BII)

Resistant to Rifamycins +/- Other Drugs:

  • Regimen and duration of treatment should be individualized based on resistance pattern, clinical and microbiological responses, and in close consultation with experienced specialists (AIII).
Adjunctive corticosteroid improves survival for TB meningitis and pericarditis (AI). See text for drug, dose, and duration recommendations.

All rifamycins may have significant pharmacokinetic interactions with antiretroviral drugs, please refer to the Drug Interactions section in the Adult and Adolescent ARV Guidelines) for dosing recommendations

Therapeutic drug monitoring should be considered in patients receiving rifamycin and interacting ART.

Paradoxical IRIS that is not severe can be treated with NSAIDs without a change in TB or HIV therapy (BIII).

For severe IRIS reaction, consider prednisone and taper over 4 weeks based on clinical symptoms (BIII).

For example:

  • If receiving RIF: prednisone 1.5 mg/kg/day for 2 weeks, then 0.75 mg/kg/day for 2 weeks
  • If receiving RFB: prednisone 1.0 mg/kg/day for 2 weeks, then 0.5 mg/kg/day for 2 weeks

A more gradual tapering schedule over a few months may be necessary for some patients.

Disseminated Myco-bacterium avium Complex (MAC) DiseaseAt Least 2 Drugs as Initial Therapy With:

  • Clarithromycin 500 mg PO BID (AI) + ethambutol 15 mg/ kg PO daily (AI), or
  • (Azithromycin 500–600 mg + ethambutol 15 mg/kg) PO daily (AII) if drug interaction or intolerance precludes the use of clarithromycin

Duration:

  • At least 12 months of therapy, can discontinue if no signs and symptoms of MAC disease and sustained (>6 months) CD4 count >100 cells/µL in response to ART
Addition of a third or fourth drug should be considered for patients with advanced immunosuppression (CD4 counts <50 cells/ µL), high mycobacterial loads (>2 log CFU/mL of blood), or in the absence of effective ART (CIII).

Third or Fourth Drug Options May Include:

  • RFB 300 mg PO daily (dosage adjustment may be necessary based on drug interactions) (CI),
  • Amikacin 10–15 mg/kg IV daily (CIII) or Strepto-mycin 1 g IV or IM daily (CIII), or
  • Moxifloxacin 400 mg PO daily (CIII) or Levofloxacin 500 mg PO daily (CIII)
Testing of susceptibility to clarithromycin and azithromycin is recommended (BIII).

NSAIDs can be used for patients who experience moderate to severe symptoms attributed to IRIS (CIII).

If IRIS symptoms persist, short-term (4–8 weeks) systemic corticosteroids (equivalent to 20–40 mg prednisone) can be used (CII).

Bacterial Respiratory Diseases
(with focus on pneumonia)
Empiric antibiotic therapy should be initiated promptly for patients presenting with clinical and radiographic evidence consistent with bacterial pneumonia. The recommendations listed are suggested empiric therapy. The regimen should be modified as needed once microbiologic results are available (BIII).Fluoroquinolones should be used with caution in patients in whom TB is suspected but is not being treated.

Empiric therapy with a macrolide alone is not routinely recommended, because of increasing pneumococcal resistance (BIII).

Patients receiving a macrolide for MAC prophylaxis should not receive macrolide monotherapy for empiric treatment of bacterial pneumonia.

For patients begun on IV antibiotic therapy, switching to PO should be considered when they are clinically improved and able to tolerate oral medications.

Chemoprophylaxis can be considered for patients with frequent recurrences of serious bacterial pneumonia (CIII).

Clinicians should be cautious about using antibiotics to prevent recurrences because of the potential for developing drug resistance and drug toxicities.

Empiric Outpatient Therapy:

  • A PO beta-lactam + a PO macrolide (azithromycin or clarithromycin) (AII)
    • Preferred beta-lactams: high-dose amoxicillin or amoxicillin/clavulanate
    • Alternative beta-lactams: cefpodoxime or cefuroxime, or
  • For penicillin-allergic patients:
    Levofloxacin 750 mg PO once daily (AII), or moxifloxacin 400 mg PO once daily (AII)

Duration: 7–10 days (a minimum of 5 days). Patients should be afebrile for 48–72 hours and clinically stable before stopping antibiotics.

Empiric Therapy for Non-ICU Hospitalized Patients:

  • An IV beta-lactam + a macrolide (azithromycin or clarithromycin) (AII)
    • Preferred beta-lactams: ceftriaxone, cefotaxime, or ampicillin-sulbactam
  • For penicillin-allergic patients:
    Levofloxacin, 750 mg IV once daily (AII), or moxifloxacin, 400 mg IV once daily (AII)

Empiric Therapy for ICU Patients:

  • An IV beta-lactam + IV azithromycin (AII), or
  • An IV beta-lactam + (levofloxacin 750 mg IV once daily or moxifloxacin 400 mg IV once daily) (AII)
    • Preferred beta-lactams: ceftriaxone, cefotaxime, or ampicillin-sulbactam

Empiric Therapy for Patients at Risk of Pseudomonas Pneumonia:

  • An IV antipneumococcal, antipseudomonal beta-lactam + (ciprofloxacin 400 mg IV q8–12h or levofloxacin 750 mg IV once daily) (BIII)
    • Preferred beta-lactams:
      piperacillin-tazobactam, cefepime, imipenem, or meropenem

Empiric Therapy for Patients at Risk for Methicillin-Resistant Staphylococcus aureus Pneumonia:

  • Add vancomycin IV or linezolid (IV or PO) to the baseline regimen (BIII)
  • Addition of clindamycin to vancomycin (but not to linezolid) can be considered for severe necrotizing pneumonia to minimize bacterial toxin production (CIII).
Empiric Outpatient Therapy:

  • A PO beta-lactam + PO doxycycline (CIII)
    • Preferred beta-lactams: high-dose amoxicillin or amoxicillin/ clavulanate
    • Alternative beta-lactams: cefpodoxime or cefuroxime

Empiric Therapy for Non-ICU Hospitalized Patients:

  • An IV beta-lactam + doxycycline (CIII)

Empiric Therapy For ICU Patients:

  • For penicillin-allergic patients: Aztreonam IV + (levofloxacin 750 mg IV once daily or moxifloxacin 400 mg IV once daily) (BIII)

Empiric Therapy for Patients at Risk of Pseudomonas Pneumonia:

  • An IV antipneumococcal, antipseudomonal beta-lactam + an aminoglycoside + azithromycin (BIII), or
  • Above beta-lactam + an aminoglycoside + (levofloxacin 750 mg IV once daily or moxifloxacin 400 mg IV once daily) (BIII), or
  • For penicillin-allergic patients: Replace the beta-lactam with aztreonam (BIII).
Bacterial Enteric Infections:

Empiric Therapy pending definitive diagnosis.

Diagnostic fecal specimens should be obtained before initiation of empiric antibiotic therapy. If culture is positive, antibiotic susceptibilities should be performed to inform antibiotic choices given increased reports of antibiotic resistance. If a culture independent diagnostic test is positive, reflex cultures for antibiotic susceptibilities should also be done.

Empiric antibiotic therapy is indicated for advanced HIV patients (CD4 count <200 cells/µL or concomitant AIDS-defining illnesses), with clinically severe diarrhea (≥6 stools/day or bloody stool) and/or accompanying fever or chills.

Empiric Therapy:

  • Ciprofloxacin 500–750 mg PO (or 400 mg IV) q12h (AIII)

Therapy should be adjusted based on the results of diagnostic work-up.

For patients with chronic diarrhea (>14 days) without severe clinical signs, empiric antibiotics therapy is not necessary, can withhold treatment until a diagnosis is made.

Empiric Therapy:

  • Ceftriaxone 1 g IV q24h (BIII), or
  • Cefotaxime 1 g IV q8h (BIII)
Oral or IV rehydration (if indicated) should be given to patients with diarrhea (AIII).

Antimotility agents should be avoided if there is concern about inflammatory diarrhea, including Clostridium-difficile-associated diarrhea (BIII).

If no clinical response after 3-4 days, consider follow-up stool culture with antibiotic susceptibility testing or alternative diagnostic tests (e.g., toxin assays, molecular testing) to evaluate alternative diagnosis, antibiotic resistance, or drug-drug interactions.

IV antibiotics and hospitalization should be considered in patients with marked nausea, vomiting, diarrhea, electrolyte abnormalities, acidosis, and blood pressure instability.

SalmonellosisAll HIV-infected patients with salmonellosis should receive antimicrobial treatment due to an increase of bacteremia (by 20-100 fold) and mortality (by up to 7-fold) compared to HIV negative individuals. (AIII)Oral or IV rehydration if indicated (AIII).

Antimotility agents should be avoided (BIII).

The role of long-term secondary prophylaxis in patients with recurrent Salmonella bacteremia is not well established. Must weigh benefit against risks of long-term antibiotic exposure (BIII).

Effective ART may reduce the frequency, severity, and recurrence of salmonella infections.

  • Ciprofloxacin 500–750 mg PO (or 400 mg IV) q12h, if susceptible (AIII)

Duration of Therapy:
For gastroenteritis without bacteremia:

  • If CD4 count ≥200 cells/µL: 7–14 days (BIII)
  • If CD4 count <200 cells/µL: 2–6 weeks (BIII)

For gastroenteritis with bacteremia:

  • If CD4 count ≥200/µL: 14 days or longer duration if bacteremia persists or if the infection is complicated (e.g., if metastatic foci of infection are present) (BIII)
  • If CD4 count <200 cells/µL: 2–6 weeks (BIII)

Secondary Prophylaxis Should Be Considered For:

  • Patients with recurrent Salmonella gastroenteritis +/- bacteremia (CIII), or
  • Patients with CD4 <200 cells/μL with severe diarrhea (CIII)
  • Levofloxacin 750 mg (PO or IV) q24h (BIII), or
  • Moxifloxacin 400 mg (PO or IV) q24h (BIII), or
  • TMP 160 mg-SMX 800 mg (PO or IV) q12h (BIII), or
  • Ceftriaxone 1 g IV q24h (BIII), or
  • Cefotaxime 1 g IV q8h (BIII)
Shigellosis
  • Ciprofloxacin 500–750 mg PO (or 400 mg IV) q12h (AIII)

Duration of Therapy:

  • Gastroenteritis: 7–10 days (AIII) (if azithromycin is used, treat for 5 days)
  • Bacteremia: ≥14 days (BIII)
  • Recurrent Infections: up to 6 weeks (BIII)

Note
Increased resistance of Shigella to fluoroquinolones is occurring in the United States. Avoid fluoroquinolones if ciprofloxacin MIC is >0.12 ug/ml even if the laboratory identifies the isolate as sensitive. Many Shigella strains resistant to fluoroquinolones exhibit resistance to other commonly used antibiotics. Thus, antibiotic sensitivity testing of Shigella isolates from HIV-infected individuals should be performed routinely.

  • Levofloxacin 750 mg (PO or IV) q24h (BIII), or
  • Moxifloxacin 400 mg (PO or IV) q24h (BIII), or
  • TMP 160 mg-SMX 800 mg (PO or IV) q12h (BIII) (Note: Shigella infections acquired outside of the United States have high rates of TMP-SMX resistance), or
  • Azithromycin 500 mg PO daily for 5 days (BIII) (Note: azithromycin is not recommended for patients with bacteremia [AIII])

Note – Azithromycin resistant Shigella spp has been reported in HIV-infected MSM

Therapy is indicated both to shorten duration of illness and prevent spread of infection (AIII).

Given increasing antimicrobial resistance and limited data showing that antibiotic therapy limits transmission, antibiotic treatment may be withheld in patients with CD4 >500 cells/mm3 whose diarrhea resolves prior to culture confirmation of Shigella infection (CIII).

Oral or IV rehydration if indicated (AIII).

Antimotility agents should be avoided (BIII).

If no clinical response after 5–7 days, consider follow-up stool culture, alternative diagnosis, or antibiotic resistance.

Effective ART may decrease the risk of recurrence of Shigella infections.

CampylobacteriosisFor Mild Disease and If CD4 Count >200 cells/μL:

  • No therapy unless symptoms persist for more than several days (CIII)

For Mild-to-Moderate Disease (If Susceptible):

  • Ciprofloxacin 500–750 mg PO (or 400 mg IV) q12h (BIII), or
  • Azithromycin 500 mg PO daily (BIII) (Note: Not for patients with bacteremia [AIII])

For Campylobacter Bacteremia:

  • Ciprofloxacin 500–750 mg PO (or 400 mg IV) q12h (BIII) + an aminoglycoside (BIII)

Duration of Therapy:

  • Gastroenteritis: 7–10 days (AIII) (5 days with azithromycin)
  • Bacteremia: ≥14 days (BIII)
  • Recurrent bacteremia: 2–6 weeks (BIII)
For Mild-to-Moderate Disease (If Susceptible)

  • Levofloxacin 750 mg (PO or IV) q24h (BIII), or
  • Moxifloxacin 400 mg (PO or IV) q24h (BIII)

Add an aminoglycoside to fluoroquinolone in bacteremic patients (BIII).

Oral or IV rehydration if indicated (AIII).

Antimotility agents should be avoided (BIII).

If no clinical response after 5–7 days, consider follow-up stool culture, alternative diagnosis, or antibiotic resistance.

There is an increasing rate of fluoroquinolone resistance in the United States (24% resistance in 2011).

The rational of addition of an aminoglycoside to a fluoroquinolone in bacteremic patients is to prevent emergence of quinolone resistance.

Effective ART may reduce the frequency, severity, and recurrence of campylobacter infections.

Clostridium difficile infection (CDI)Vancomycin 125 mg (PO) QID for 10-14 days (AI)

For severe, life-threatening CDI, see text and references for additional information.

For mild, outpatient disease: metronidazole 500 mg (PO) TID for 10–14 days (CII)Recurrent CDI:

Treatment is the same as in patients without HIV infection. Fecal microbiota therapy may be successful and safe to treat recurrent CDI in HIV-infected patients (CIII). See text and references for additional information.

BartonellosisFor Bacillary Angiomatosis, Peliosis Hepatis, Bacteremia, and Osteomyelitis:

  • Doxycycline 100 mg PO or IV q12h (AII), or
  • Erythromycin 500 mg PO or IV q6h (AII)

CNS Infections:

  • (Doxycycline 100 mg +/- RIF 300 mg) PO or IV q12h (AIII)

Confirmed Bartonella Endocarditis:

  • (Doxycycline 100 mg IV q12h + gentamicin 1 mg/kg IV q8h) for 2 weeks, then continue with doxycycline 100 mg IV or PO q12h (BII)

Other Severe Infections:

  • (Doxycycline 100 mg PO or IV +/- RIF 300 mg PO or IV) q12h (BIII), or
  • (Erythromycin 500 mg PO or IV q6h) +/- RIF 300 mg PO or IV q12h (BIII)

Duration of Therapy:

  • At least 3 months (AII)
For Bacillary Angiomatosis, Peliosis Hepatis, Bacteremia, And Osteomyelitis:

  • Azithromycin 500 mg PO daily (BIII)
  • Clarithromycin 500 mg PO BID (BIII)

Confirmed Bartonella Endocarditis but with Renal Insufficiency:

  • (Doxycycline 100 mg IV + RIF 300 mg PO or IV) q12h for 2 weeks, then continue with doxycycline 100 mg IV or PI q12h (BII)
When RIF is used, take into consideration the potential for significant interaction with ARV drugs and other medications (see Table 5 for dosing recommendations).

If relapse occurs after initial (>3 month) course of therapy, long-term suppression with doxycycline or a macrolide is recommended as long as CD4 count <200 cells/µL (AIII).

Syphilis (Treponema pallidum Infection)Early Stage (Primary, Secondary, and Early-Latent Syphilis):

  • Benzathine penicillin G 2.4 million units IM for 1 dose (AII)

Late-Latent Disease (>1 year or of Unknown Duration, and No Signs of Neurosyphilis):

  • Benzathine penicillin G 2.4 million units IM weekly for 3 doses (AII)

Late-Stage (Tertiary–Cardiovascular or Gummatous Disease):

  • Benzathine penicillin G 2.4 million units IM weekly for 3 doses (AII) (Note: rule out neurosyphilis before initiation of benzathine penicillin, and obtain infectious diseases consultation to guide management)

Neurosyphilis (Including Otic or Ocular Disease):

  • Aqueous crystalline penicillin G 18–24 million units per day (administered as 3–4 million units IV q4h or by continuous IV infusion) for 10–14 days (AII) +/- benzathine penicillin G 2.4 million units IM weekly for 3 doses after completion of IV therapy (CIII)
Early Stage (Primary, Secondary, and Early-Latent Syphilis):
For penicillin-allergic patients

  • Doxycycline 100 mg PO BID for 14 days (BII), or
  • Ceftriaxone 1 g IM or IV daily for 10–14 days (BII), or
  • Azithromycin 2 g PO for 1 dose (BII) (Note: azithromycin is not recommended for men who have sex with men or pregnant women (AII))

Late-Latent Disease (>1 year or of Unknown Duration, and No Signs of Neurosyphilis):
For penicillin-allergic patients

  • Doxycycline 100 mg PO BID for 28 days (BIII)

Neurosyphilis:

  • Procaine penicillin 2.4 million units IM daily plus probenecid 500 mg PO QID for 10–14 days (BII) +/- benzathine penicillin G 2.4 million units IM weekly for 3 doses after completion of above (CIII), or
  • For penicillin-allergic patients: Desensitization to penicillin is the preferred approach (BIII); if not feasible, ceftriaxone, 2 g IV daily for 10–14 days (BII)
The efficacy of non-penicillin alternatives has not been evaluated in HIV-infected patients and they should be used only with close clinical and serologic monitoring.

Combination of procaine penicillin and pro-benecid is not recommended for patients who are allergic to sulfa-containing medications (AIII).

The Jarisch-Herxheimer reaction is an acute febrile reaction accompanied by headache and myalgia that can occur within the first 24 hours after therapy for syphilis. This reaction occurs most frequently in patients with early syphilis, high non-treponemal titers, and prior penicillin treatment.

Mucocutaneous candidiasisFor Oropharyngeal Candidiasis; Initial Episodes (For 7–14 Days):
Oral Therapy

  • Fluconazole 100 mg PO daily (AI)

For Esophageal Candidiasis (For 14–21 Days):

  • Fluconazole 100 mg (up to 400 mg) PO or IV daily (AI), or
  • Itraconazole oral solution 200 mg PO daily (AI)

For Uncomplicated Vulvo-Vaginal Candidiasis:

  • Oral fluconazole 150 mg for 1 dose (AII), or
  • Topical azoles (clotrimazole, butoconazole, miconazole, tioconazole, or terconazole) for 3–7 days (AII)

For Severe or Recurrent Vulvo-Vaginal Candidiasis:

  • Fluconazole 100–200 mg PO daily for ≥7 days (AII), or
  • Topical antifungal ≥7 days (AII)
For Oropharyngeal Candidiasis; Initial Episodes (For 7–14 Days):
Oral Therapy

  • Itraconazole oral solution 200 mg PO daily (BI), or
  • Posaconazole oral suspension 400 mg PO BID for 1 day, then 400 mg daily (BI)

Topical Therapy

  • Clotrimazole troches, 10 mg PO 5 times daily (BI), or
  • Miconazole mucoadhesive buccal 50-mg tablet—apply to mucosal surface over the canine fossa once daily (do not swallow, chew, or crush) (BI), or
  • Nystatin suspension 4–6 mL QID or 1–2 flavored pastilles 4–5 times daily (BII)

For Esophageal Candidiasis (For 14–21 Days):

  • Voriconazole 200 mg PO or IV BID (BI), or
  • Isavuconazole 200mg PO as a loading dose, followed by 50 mg PO daily (BI), or
  • Isavuconazole 400mg PO as a loading dose, followed by 100 mg PO daily (BI), or
  • Isavuconazole 400 mg PO once-weekly (BI), or
  • Anidulafungin 100 mg IV 1 time, then 50 mg IV daily (BI), or
  • Caspofungin 50 mg IV daily (BI), or
  • Micafungin 150 mg IV daily (BI), or
  • Amphotericin B deoxycholate 0.6 mg/kg IV daily (BI), or
  • Lipid formulation of amphotericin B 3–4 mg/kg IV daily (BIII)

For Uncomplicated Vulvo-Vaginal Candidiasis:

  • Itraconazole oral solution 200 mg PO daily for 3–7 days (BII)
Chronic or prolonged use of azoles may promote development of resistance.

Higher relapse rate for esophageal candidiasis seen with echin-ocandins than with fluconazole use.

Suppressive therapy usually not recommended (BIII) unless patients have frequent or severe recurrences.

If Decision Is to Use Suppressive Therapy:
Oropharyngeal candidiasis:

  • Fluconazole 100 mg PO daily or three times weekly (BI); or
  • Itraconazole oral solution 200 mg PO daily (CI)

Esophageal candidiasis:

  • Fluconazole 100–200 mg PO daily (BI); or
  • Posaconazole 400 mg PO BID (BII)

Vulvo-vaginal candidiasis:

  • Fluconazole 150 mg PO once weekly (CII)
CryptococcosisCryptococcal Meningitis
Induction Therapy (for at least 2 weeks, followed by consolidation therapy):

  • Liposomal amphotericin B 3–4 mg/kg IV daily + flucytosine 25 mg/kg PO QID (AI) (Note: Flucytosine dose should be adjusted in patients with renal dysfunction.)

Consolidation Therapy (for at least 8 weeks (AI), followed by maintenance therapy):

  • Fluconazole 400 mg PO (or IV) daily (AI)

Maintenance Therapy:

  • Fluconazole 200 mg PO daily for at least 12 months (AI)

For Non-CNS, Extrapulmonary Cryptococcosis and Diffuse Pul-monary Disease:

  • Treatment same as for cryptococcal meningitis (BIII)

Non-CNS Cryptococcosis with Mild-to-Moderate Symptoms and Focal Pulmonary Infiltrates:

  • Fluconazole, 400 mg PO daily for 12 months (BIII)
Cryptococcal meningitis
Induction Therapy (for at least 2 weeks, followed by consolidation therapy):

  • Amphotericin B deoxycholate 0.7 mg/kg IV daily + flucytosine 25 mg/kg PO QID (AI), or
  • Amphotericin B lipid complex 5 mg/kg IV daily + flucytosine 25 mg/kg PO QID (BII), or
  • Liposomal amphotericin B 3-4 mg/kg IV daily + fluconazole 800 mg PO or IV daily (BIII), or
  • Amphotericin B deoxycholate 0.7 mg/kg IV daily + fluconazole 800 mg PO or IV daily (BI), or
  • Fluconazole 400–800 mg PO or IV daily + flucyto-sine 25 mg/kg PO QID (BII), or
  • Fluconazole 1200 mg PO or IV daily (CII)

Consolidation Therapy (for at least 8 weeks (AI), followed by maintenance therapy):

  • Itraconazole 200 mg PO BID for 8 weeks—less effective than fluconazole (CI)

Maintenance Therapy:

  • No alternative therapy recommendation
Addition of flucytosine to amphotericin B has been associated with more rapid sterilization of CSF and decreased risk for subsequent relapse.

Patients receiving flucytosine should have either blood levels monitored (peak level 2 hours after dose should be 30–80 mcg/mL) or close monitoring of blood counts for development of cytopenia. Dosage should be adjusted in patients with renal insufficiency (BII).

Opening pressure should always be measured when an LP is performed (AII). Repeated LPs or CSF shunting are essential to effectively manage increased intracranial pressure (BIII).

Corticosteroids and mannitol are ineffective in reducing ICP and are NOT recommended (BII).

Corticosteroid should not be routinely used during induction therapy unless it is for the management of IRIS (AI).

HistoplasmosisModerately Severe to Severe Disseminated Disease
Induction Therapy (for at least 2 weeks or until clinically improved):

  • Liposomal amphotericin B 3 mg/kg IV daily (AI)

Maintenance Therapy

  • Itraconazole 200 mg PO TID for 3 days, then 200 mg PO BID (AII)

Less Severe Disseminated Disease
Induction and Maintenance Therapy:

  • Itraconazole 200 mg PO TID for 3 days, then 200 mg PO BID (AII)

Duration of Therapy:

  • At least 12 months

Meningitis
Induction Therapy (4–6 weeks):

  • Liposomal amphotericin B 5 mg/kg/day (AIII)

Maintenance Therapy:

  • Itraconazole 200 mg PO BID to TID for ≥1 year and until resolution of abnormal CSF findings (AII)

Long-Term Suppression Therapy:
For patients with severe disseminated or CNS infection (AIII) after completion of at least 12 months of therapy; and those who relapse despite appropriate therapy (BIII):

  • Itraconazole 200 mg PO daily (AIII)
Moderately Severe to Severe Disseminated Disease
Induction Therapy (for at least 2 weeks or until clinically improved):

  • Amphotericin B lipid complex 3 mg/kg IV daily (AIII), or
  • Amphotericin B cholesteryl sulfate complex 3 mg/kg IV daily (AIII)

Alternatives to Itraconazole for Maintenance Therapy or Treatment of Less Severe Disease:

  • Voriconazole 400 mg PO BID for 1 day, then 200 mg BID (BIII), or
  • Posaconazole 400 mg PO BID (BIII)
  • Fluconazole 800 mg PO daily (CII)

Meningitis:

  • No alternative therapy recommendation

Long-Term Suppression Therapy:

  • Fluconazole 400 mg PO daily (BIII)
Itraconazole, posaconazole, and voriconazole may have significant interactions with certain ARV agents. These interactions are complex and can be bi-directional. Refer to Table 5 for dosage recommendations.

Therapeutic drug monitoring and dosage adjustment may be necessary to ensure triazole antifungal and ARV efficacy and reduce concentration-related toxicities.

Random serum concentration of itraconazole + hydroitraconazole should be >1 μg/mL.

Clinical experience with voriconazole or posaconazole in the treatment of histoplasmosis is limited.

Acute pulmonary histoplasmosis in HIV-infected patients with CD4 counts >300 cells/µL should be managed as non-immunocompromised host (AIII).

CoccidioidomycosisClinically Mild Infections (e.g., Focal Pneumonia):

  • Fluconazole 400 mg* PO daily (AII), or
  • Itraconazole 200 mg* PO BID (BII)

Bone or Joint Infections:

  • Itraconazole 200 mg* PO BID (AI)

Severe, Non-Meningeal Infection (Diffuse Pulmonary Infection or Severely Ill Patients with Extrathoracic, Disseminated Disease):

  • Lipid formulation amphotericin B 3-5 mg/kg IV daily (AIII), or
  • Amphotericin B deoxycholate 0.7–1.0 mg/kg IV daily (AII)
  • Duration of therapy: continue until clinical improvement, then switch to a triazole (BIII)

Meningeal Infections:

  • Fluconazole 400–800 mg* IV or PO daily (AII)
Mild Infections (Focal Pneumonia)
For Patients Who Failed to Respond to Fluconazole or Itraconazole:

  • Posaconazole 300 mg delayed-release tablet* PO BID x 1 day, then once daily (BIII), or
  • Posaconazole 400 mg oral suspension* PO BID (BII), or
  • Voriconazole 200 mg* PO BID (BIII)

Bone or Joint Infection:

  • Fluconazole 400 mg* PO daily (BI)

Severe, Non-Meningeal Infection (Diffuse Pulmonary Infection or Severely Ill Patients with Extrathoracic, Disseminated Disease):

  • Some specialists will add a triazole (fluconazole* or itraconazole*) 400 mg per day to amphotericin B therapy and continue triazole once amphotericin B is stopped (BIII).

Meningeal Infections:

  • Itraconazole 200 mg* PO TID for 3 days, then 200 mg PO BID (BII), or
  • Voriconazole 200–400 mg * PO BID (BIII), or
  • Posaconazole 300mg delayed-release tablet* PO BID x 1 day, then once daily (CIII), or
  • Posaconazole 400 mg oral suspension* PO BID (CIII), or
  • Intrathecal amphotericin B deoxycholate, when triazole antifungals are ineffective (AIII)
Relapse can occur in 25%–33% of HIV-negative patients with diffuse pulmonary or disseminated diseases . Therapy should be given for at least 12 months and usually much longer; discontinuation is dependent on clinical and serological response and should be made in consultation with experts (BIII).

Therapy should be lifelong in patients with meningeal infections because relapse occurs in 80% of HIV-infected patients after discontinuation of triazole therapy (AII).

* Fluconazole, itraconazole, posaconazole, and voriconazole may have significant interactions with other medications including ARV drugs. These interactions are complex and can be bi- directional. Refer to Table 5 or Antiretroviral guidelines for dosage recommendations. Therapeutic drug monitoring and dosage adjustment may be necessary to ensure triazole antifungal and antiretroviral efficacy and reduce concentration-related toxicities.

Intrathecal amphotericin B should only be given in consultation with a specialist and administered by an individual with experience with the technique.

Cytomegalovirus (CMV) DiseaseCMV Retinitis
Induction Therapy (followed by Chronic Maintenance Therapy)
For Immediate Sight-Threatening Lesions (within 1500 microns of the fovea):

  • Intravitreal injections of ganciclovir (2mg) or foscarnet (2.4mg) for 1-4 doses over a period of 7- 10 days to achieve high intraocular concentration faster (AIII); plus
  • Valganciclovir 900 mg PO BID for 14– 21 days, then 900 mg once daily (AI)

For Peripheral Lesions

  • Valganciclovir 900 mg PO BID for 14– 21 days, then 900 mg once daily (AI)

Chronic Maintenance

  • Valganciclovir 900 mg PO daily (AI) for 3-6 months until ART induced immune recovery (see Table 4)

CMV Esophagitis or Colitis:

  • Ganciclovir 5 mg/kg IV q12h; may switch to valgan-ciclovir 900 mg PO q12h once the patient can tolerate oral therapy (BI)
  • Duration: 21–42 days or until symptoms have resolved (CII)
  • Maintenance therapy is usually not necessary, but should be considered after relapses (BII).

Well-Documented, Histologically Confirmed CMV Pneumonia:

  • Experience for treating CMV pneumonitis in HIV patients is limited. Use of IV ganciclovir or IV foscarnet is reasonable (doses same as for CMV retinitis) (CIII).
  • The optimal duration of therapy and the role of oral valganciclovir have not been established.

CMV Neurological Disease
Note: Treatment should be initiated promptly.

  • Ganciclovir 5 mg/kg IV q12h + (foscarnet 90 mg/kg IV q12h or 60 mg/kg IV q8h) to stabilize disease and maximize response, continue until symptomatic improvement and resolution of neurologic symptoms (CIII)
  • The optimal duration of therapy and the role of oral valganciclovir have not been established.
  • Optimize ART to achieve viral suppression and immune reconstitution (BIII)
CMV Retinitis
For Immediate Sight-Threatening Lesions (within 1500 microns of the fovea): Intravitreal therapy as listed in the Preferred section, plus one of the following:

Alternative Systemic Induction Therapy (followed by Chronic Maintenance Therapy)

  • Ganciclovir 5 mg/kg IV q12h for 14–21 days (AI), or
  • Foscarnet 90 mg/kg IV q12h or 60 mg/kg q8h for 14–21 days (AI), or
  • Cidofovir 5 mg/kg/week IV for 2 weeks; saline hydration before and after therapy and probenecid, 2 g PO 3 hours before dose, followed by 1 g PO 2 hours and 8 hours after the dose (total of 4 g) (BI). (Note: This regimen should be avoided in patients with sulfa allergy because of cross hypersensitivity with probenecid.)

Chronic Maintenance (for 3-6 months until ART induced immune recovery) (see Table 4):

  • Ganciclovir 5 mg/kg IV 5–7 times weekly (AI), or
  • Foscarnet 90–120 mg/kg IV once daily (AI), or
  • Cidofovir 5 mg/kg IV every other week with saline hydration and probenecid as above (BI)

CMV Esophagitis or Colitis:

  • Foscarnet 90 mg/kg IV q12h or 60 mg/kg q8h (BI) for patients with treatment-limiting toxicities to ganciclovir or with ganciclovir resistance, or
  • Valganciclovir 900 mg PO q12h in milder disease and if able to tolerate PO therapy (BII), or
  • Duration: 21–42 days or until symptoms have resolved (CII)
  • For mild disease, if ART can be initiated without delay, consider withholding CMV therapy (CIII).
The choice of therapy for CMV retinitis should be individualized, based on location and severity of the lesions, level of immunosuppression, and other factors (e.g., concomitant medications and ability to adhere to treatment) (AIII).

Given the evident benefits of systemic therapy in preventing contralateral eye involvement, reduce CMV visceral disease and improve survival, whenever feasible, treatment should include systemic therapy

The ganciclovir ocular implant, which is effective for treatment of CMV retinitis is no longer available. For sight threatening retinitis, intra-vitreal injections of ganciclovir or foscarnet can be given to achieve higher ocular concentration faster.

Routine (i.e., every 3 months) ophthalmologic follow-up is recommended after stopping chronic maintenance therapy for early detection of relapse or IRU, and then periodically after sustained immune reconstitution (AIII).

IRU may develop in the setting of immune reconstitution.

Treatment of IRU

  • Periocular corticosteroid or short courses of systemic steroid (BIII).

Initial therapy in patients with CMV retinitis, esophagitis, colitis, and pneumonitis should include initiation or optimization of ART (BIII).

Herpes Simplex Virus (HSV) DiseaseOrolabial Lesions (For 5–10 Days):

  • Valacyclovir 1 g PO BID (AIII), or
  • Famciclovir 500 mg PO BID (AIII), or
  • Acyclovir 400 mg PO TID (AIII)

Initial or Recurrent Genital HSV (For 5–14 Days):

  • Valacyclovir 1 g PO BID (AI), or
  • Famciclovir 500 mg PO BID (AI), or
  • Acyclovir 400 mg PO TID (AI)

Severe Mucocutaneous HSV:

  • Initial therapy acyclovir 5 mg/kg IV q8h (AIII)
  • After lesions begin to regress, change to PO therapy as above. Continue until lesions are completely healed.

Chronic Suppressive Therapy
For patients with severe recurrences of genital herpes (AI) or patients who want to minimize frequency of recurrences (AI):

  • Valacyclovir 500 mg PO BID (AI)
  • Famciclovir 500 mg PO BID (AI)
  • Acyclovir 400 mg PO BID (AI)
  • Continue indefinitely regardless of CD4 cell count.
For Acyclovir-Resistant HSV
Preferred Therapy:

  • Foscarnet 80–120 mg/kg/day IV in 2–3 divided doses until clinical response (AI)

Alternative Therapy (CIII):

  • IV cidofovir (dosage as in CMV retinitis), or
  • Topical trifluridine, or
  • Topical cidofovir, or
  • Topical imiquimod

Duration of Therapy:

  • 21–28 days or longer
Patients with HSV infections can be treated with episodic therapy when symptomatic lesions occur, or with daily suppressive therapy to prevent recurrences.

Topical formulations of trifluridine and cidofovir are not commercially available.

Extemporaneous compounding of topical products can be prepared using trifluridine ophthalmic solution and the IV formulation of cidofovir.

Varicella Zoster Virus (VZV) DiseasePrimary Varicella Infection (Chickenpox)
Uncomplicated Cases (For 5–7 Days):

  • Valacyclovir 1 g PO TID (AII), or
  • Famciclovir 500 mg PO TID (AII)

Severe or Complicated Cases:

  • Acyclovir 10–15 mg/kg IV q8h for 7–10 days (AIII)
  • May switch to oral valacyclovir, famciclovir, or acyclovir after defervescence if no evidence of visceral involvement (BIII).

Herpes Zoster (Shingles)
Acute Localized Dermatomal:

  • For 7–10 days; consider longer duration if lesions are slow to resolve
  • Valacyclovir 1 g PO TID (AII), or
  • Famciclovir 500 mg TID (AII)

Extensive Cutaneous Lesion or Visceral Involvement:

  • Acyclovir 10–15 mg/kg IV q8h until clinical improvement is evident (AII)
  • May switch to PO therapy (valacyclovir, famciclovir, or acyclovir) after clinical improvement (i.e., when no new vesicle formation or improvement of signs and symptoms of visceral VZV), to complete a 10–14 day course (BIII).

Progressive Outer Retinal Necrosis (PORN):

  • (Ganciclovir 5 mg/kg +/- foscarnet 90 mg/kg) IV q12h + (ganciclovir 2 mg/0.05 mL +/- foscarnet 1.2 mg/0.05 mL) intravitreal injection BIW (AIII),
  • Initiate or optimize ART (AIII)

Acute Retinal Necrosis (ARN):

  • (Acyclovir 10-15 mg/kg IV q8h) + (ganciclovir 2 mg/0.05 mL intravitreal injection BIW X 1-2 doses) for 10–14 days, followed by valacyclovir 1 g PO TID for 6 weeks (AIII)
Primary Varicella Infection (Chickenpox)
Uncomplicated Cases (For 5-7 Days):

  • Acyclovir 800 mg PO 5 times/day (BII)

Herpes Zoster (Shingles)
Acute Localized Dermatomal:

  • For 7–10 days; consider longer duration if lesions are slow to resolve
  • Acyclovir 800 mg PO 5 times/day (BII)
In managing VZV retinitis – Consultation with an ophthalmologist experienced in management of VZV retinitis is strongly recommended (AIII).

Duration of therapy for VZV retinitis is not well defined, and should be determined based on clinical, virologic, and immunologic responses and ophthalmologic responses.

Optimization of ART is recommended for serious and difficult-to-treat VZV infections (e.g., retinitis, encephalitis) (AIII).

HHV-8 Diseases
(Kaposi Sarcoma [KS], Primary Effusion Lymphoma [PEL], Multicentric Castleman’s Disease [MCD])
Mild To Moderate KS (localized involvement of skin and/or lymph nodes):

  • Initiate or optimize ART (AII)

Advanced KS [visceral (AI) or disseminated cutaneous KS (BIII)]:

  • Chemotherapy (per oncology consult) + ART
  • Liposomal doxorubin first line chemotherapy (AI)

Primary Effusion Lymphoma:

  • Chemotherapy (per oncology consult) + ART (AIII)
  • PO valganciclovir or IV ganciclovir can be used as adjunctive therapy (CIII).

MCD Therapy Options (in consultation with specialist, depending on HIV/HHV-8 status, presence of organ failure, and refractory nature of disease):

ART (AIII) along with one of the following

  • Valganciclovir 900 mg PO BID for 3 weeks (CII), or
  • Ganciclovir 5 mg/kg IV q12h for 3 weeks (CII), or
  • Valganciclovir PO or Ganciclovir IV + zidovudine 600 mg PO q6h for 7–21 days (CII)
  • Rituximab +/- Prednisone (CII)
  • Monoclonal antibody targeting IL-6 or IL-6 receptor (BII)

Concurrent KS and MCD

  • Rituximab + liposomal doxorubicin (BII)
MCD

  • Rituximab (375 mg/m2 given weekly for 4–8 weeks) may be an alternative to or used adjunctively with antiviral therapy (CII).
  • Corticosteroids should be avoided in patients with KS, including those with KS-IRis (AIII)
  • Corticosteroids are potentially effective as adjunctive therapy for MCD, but should be used with caution, esp. in patients with concurrent KS.
  • Patients who received rituximab for MCD may experience subsequent exacerbation or emergence of KS.
Human Papillomavirus (HPV) DiseaseTreatment of Condyloma Acuminata (Genital Warts)HIV-infected patients may have larger or more numerous warts and may not respond as well to therapy for genital warts when compared to HIV-uninfected individuals.

Topical cidofovir has activity against genital warts, but the product is not commercially available (CIII).

Intralesional interferon-alpha is usually not recommended because of high cost, difficult administration, and potential for systemic side effects (CIII).

The rate of recurrence of genital warts is high despite treatment in HIV-infected patients.

There is no consensus on the treatment of oral warts. Many treatments for anogenital warts cannot be used in the oral mucosa. Surgery is the most common treatment for oral warts that interfere with function or for aesthetic reasons.

Patient-Applied Therapy for Uncomplicated External Warts That Can Be Easily Identified by Patients:

  • Podophyllotoxin (e.g., podofilox 0.5% solution or 0.5% gel): Apply to all lesions BID for 3 consecutive days, followed by 4 days of no therapy, repeat weekly for up to 4 cycles, until lesions are no longer visible (BIII), or
  • Imiquimod 5% cream: Apply to lesion at bedtime and remove in the morning on 3 non-consecutive nights weekly for up to 16 weeks, until lesions are no longer visible. Each treatment should be washed with soap and water 6–10 hours after application (BII), or
  • Sinecatechins 15% ointment: Apply to affected areas TID for up to 16 weeks, until warts are completely cleared and not visible (BIII).
Provider-Applied Therapy for Complex or Multicentric Lesions, or Lesions Inaccessible to Patient
Applied Therapy:

  • Cryotherapy (liquid nitrogen or cryoprobe): Apply until each lesion is thoroughly frozen. Repeat every 1–2 weeks for up to 4 weeks, until lesions are no longer visible (BIII). Some providers allow the lesion to thaw, then freeze a second time in each session (BIII), or
  • Trichloroacetic acid or bichloroacetic acid cauterization: 80%–90% aqueous solution, apply to wart only, allow to dry until a white frost develops. Repeat weekly for up to 6 weeks, until lesions are no longer visible (BIII), or
  • Surgical excision (BIII) or laser surgery (CIII) to external or anal warts, or
  • Podophyllin resin 10%–25% in tincture of benzoin: Apply to all lesions (up to 10 cm2), then wash off a few hours later, repeat weekly for up to 6 weeks until lesions are no longer visible (CIII).
Hepatitis B Virus (HBV) DiseaseART regimen which includes 2 drugs that are active against both HBV and HIV is recommended for all HIV/HBV-co-infected patients regardless of CD4 cell count and HBV DNA level (AII).

Tenofovir alafenamide (TAF)/ emtricitabine or tenofovir disoproxil fumerate (TDF)/emtricitabine PO once daily (+ additional drug (s) for HIV) (AIII).

The choice of TAF vs. TDF should be based on renal function and risk of renal or bone toxicities.

CrCl > 60 mL/min
TDF 300 mg plus (FTC 200 mg or 3TC 300 mg)] or [TAF (10 or 25 mg)a plus FTC 200 mg] PO once daily (AIII).

CrCl 30-59 mL/min
TAF (10 or 25 mg)a + FTC 200 mg PO once daily (AIII)

CrCl < 30 mL/min
A fully suppressive ART regimen without tenofovir should be used, with the addition of renally dosed entecavir to the regimen

Duration:
Continue treatment indefinitely (AIII)

If TAF or TDF Cannot Be Used as Part of HIV/HBV Therapy:
Use entecavir (dose adjustment according to renal function) plus a fully suppressive ART regimen without TAF or TDF (BIII).

CrCl < 30 mL/min
ART with renally dose adjusted TDF and FTC can be used (BIII) if recovery of renal function is unlikely (See Table 7 for dosage recommendation)

If patient is not receiving ART:

  • HBV treatment is indicated for elevated ALT, HBV DNA >2000mIU/mL, significant liver fibrosies, advanced liver disease or cirrhosis (AI)
  • Peginterferon alfa-2a 180 μg SQ once weekly for 48 weeks (CIII), or
  • Peginterferon alfa 2b 1.5 μg/kg SQ once weekly for 48 weeks (CIII)
Chronic administration of lamivudine or emtricitabine as the only active drug against HBV should be avoided because of high rate of selection of HBV resistance (AI).

Directly acting HBV drugs such as adefovir, emtricitabine, entecavir, lamivudine, telbivudine, or tenofovir must not be given in the absence of a fully suppressive ART regimen to avoid selection of drug resistance HIV (AI).

When changing ART regimens, continue agents with anti-HBV activity (BIII).

If anti-HBV therapy is discontinued and a flare occurs, therapy should be re-instituted because it can be potentially life-saving (AIII).

As HBV reactivation can occur during treatment for HCV with directly active agents (DAAs) in the absence of HBV-active drugs, all HIV-HBV-coinfected patients who will be treated for HCV should be on HBV-active ART at the time of HCV treatment initiation (AII)

Hepatitis C Virus (HCV) DiseaseThe field of HCV drug development is evolving rapidly. The armamenarium of approved drugs is likely to expand considerably in the next few years. Clinicians should refer to the most recent up-to-date HCV treatment guidelines (http://www.hcvguidelines.org) for the most updated recommendations.
Progressive Multifocal Leukoencephalopathy (PML) (JC Virus Infections)There is no specific antiviral therapy for JC virus infection. The main treatment approach is to reverse the immunosuppression caused by HIV.

Initiate ART immediately in ART-naive patients (AII).

Optimize ART in patients who develop PML in phase of HIV viremia on ART (AIII)

None.Corticosteroids may be used for PML-IRIS characterized by contrast enhancement, edema or mass effect, and with clinical deterioration (BIII) (see text for further discussion).
MalariaBecause Plasmodium falciparum malaria can progress within hours from mild symptoms or low-grade fever to severe disease or death, all HIV-infected patients with confirmed or suspected P. falciparum infection should be hospitalized for evaluation, initiation of treatment, and observation (AIII).

Treatment recommendations for HIV-infected patients are the same as HIV-uninfected patients (AIII).

Choice of therapy is guided by the degree of parasitemia, the species of Plasmodium, the patient’s clinical status, region of infection, and the likely drug susceptibility of the infected species, and can be found at http://www.cdc.gov/malaria.

When suspicion for malaria is low, antimalarial treatment should not be initiated until the diagnosis is confirmed.For treatment recommendations for specific regions, clinicians should refer to the following web link:
http://www.cdc.gov/malaria/
or call the CDC Malaria Hotline:
(770) 488-7788: M–F 8 AM–4:30 PM ET, or (770) 488-7100 after hours
Leishmaniasis, visceralFor Initial Infection:

  • Liposomal amphotericin B 2–4 mg/kg IV daily (AII), or
  • Liposomal amphotericin B interrupted schedule (e.g., 4 mg/ kg on days 1–5, 10, 17, 24, 31, 38) (AII)
  • To achieve total dose of 20–60 mg/kg (AII)

Chronic Maintenance Therapy (Secondary Prophylaxis); Especially in Patients with CD4 Count <200 cells/µL:

  • Liposomal amphotericin B 4 mg/kg every 2–4 weeks (AII), or
  • Amphotericin B lipid complex (AII) 3 mg/kg every 21 days (AII)
For Initial Infection:

  • Other lipid formulation of amphotericin B, dose and schedule as in Preferred Therapy, or
  • Amphotericin B deoxycholate 0.5–1.0 mg/kg IV daily for total dose of 1.5–2.0 g (BII), or
  • Sodium stibogluconate (pentavalent antimony) (BII) 20 mg/kg IV or IM daily for 28 days.

Another Option:

  • Miltefosine 100 mg PO daily for 4 weeks (available in the United States under a treatment IND) (CIII)

Chronic Maintenance Therapy (Secondary Prophylaxis):
Sodium stibogluconate 20 mg/kg IV or IM every 4 weeks (BII)

ART should be initiated or optimized (AIII).
For sodium stibogluconate, contact the CDC Drug Service at (404) 639-3670 or [email protected]
Leishmaniasis, cutaneous
  • Liposomal amphotericin B 2–4 mg/kg IV daily for 10 days (BIII), or
  • Liposomal amphotericin B interrupted schedule (e.g., 4 mg/ kg on days 1–5, 10, 17, 24, 31, 38) to achieve total dose of 20–60 mg/kg (BIII), or
  • Sodium stibogluconate 20 mg/kg IV or IM daily for 3–4 weeks (BIII)

Chronic Maintenance Therapy:
May be indicated in immunocompromised patients with multiple relapses (CIII)

Possible Options Include:

  • Oral miltefosine (can be obtained via a treatment IND), or
  • Topical paromomycin, or
  • Intralesional sodium stibogluconate, or
  • Local heat therapy

No data exist for any of these agents in HIV-infected patients; choice and efficacy dependent on species of Leishmania.

None.
Chagas Disease (American Trypanosomiasis)For Acute, Early Chronic, and Re-Activated Disease:

  • Benznidazole 5–8 mg/kg/day PO in 2 divided doses for 30–60 days (BIII) (not commercially available in the United States; contact the CDC Drug Service at [email protected] or (404) 639-3670, or the CDC emergency operations center at (770) 488-7100)
For Acute, Early Chronic, And Reactivated Disease:

  • Nifurtimox 8–10 mg/kg/day PO for 90–120 days (CIII) (not commercially available in the U.S., contact the CDC Drug Service at [email protected] or (404) 639-3670, or the CDC emergency operations center at (770) 488-7100)
Treatment is effective in reducing parasitemia and preventing clinical symptoms or slowing disease progression. It is ineffective in achieving parasitological cure.

Duration of therapy has not been studied in HIV-infected patients.

Initiate or optimize ART in patients undergoing treatment for Chagas disease, once they are clinically stable (AIII).

Penicilliosis marneffeiFor Acute Infection in Severely Ill Patients:

  • Liposomal amphotericin B 3–5 mg/kg/day IV for 2 weeks, followed by itraconazole 200 mg PO BID for 10 weeks (AII), followed by chronic maintenance therapy (as below)

For Mild Disease:

  • Itraconazole 200 mg PO BID for 8 weeks (BII); followed by chronic maintenance therapy (as below)

Chronic Maintenance Therapy (Secondary Prophylaxis):

  • Itraconazole 200 mg PO daily (AI)
For Acute Infection in Severely Ill Patients:

  • Voriconazole 6 mg/kg IV q12h for 1 day, then 4 mg/kg IV q12h for at least 3 days, followed by 200 mg PO BID for a maximum of 12 weeks (BII), followed by maintenance therapy

For Mild Disease:

  • Voriconazole 400 mg PO BID for 1 day, then 200 mg BID for a maximum of 12 weeks (BII), followed by chronic maintenance therapy
ART should be initiated simultaneously with treatment for penicilliosis to improve treatment outcome (CIII).

Itraconazole and voriconazole may have significant interactions with certain ARV agents. These interactions are complex and can be bi-directional. Refer to Table 5 for dosage recommendations.

Therapeutic drug monitoring and dosage adjustment may be necessary to ensure triazole antifungal and ARV efficacy and reduce concentration-related toxicities.

IsosporiasisFor Acute Infection:

  • TMP-SMX (160 mg/800 mg) PO (or IV) QID for 10 days (AII), or
  • TMP-SMX (160 mg/800 mg) PO (or IV) BID for 7–10 days (BI)
  • Can start with BID dosing first and increase daily dose and/ or duration (up to 3–4 weeks) if symptoms worsen or persist (BIII)
  • IV therapy may be used for patients with potential or documented mal-absorption.

Chronic Maintenance Therapy (Secondary Prophylaxis):

  • In patients with CD4 count <200/µL, TMP-SMX (160 mg/ 800 mg) PO three times weekly (AI)
For Acute Infection:

  • Pyrimethamine 50–75 mg PO daily + leucovorin 10–25 mg PO daily (BIII), or
  • Ciprofloxacin 500 mg PO BID for 7 days (CI) as a second line alternative

Chronic Maintenance Therapy (Secondary Prophylaxis):

  • TMP-SMX (160 mg/800 mg) PO daily or (320 mg/1600 mg) three times weekly (BIII)
  • Pyrimethamine 25 mg PO daily + leucovorin 5–10 mg PO daily (BIII)
  • Ciprofloxacin 500 mg three times weekly (CI) as a second-line alternative
Fluid and electrolyte management in patients with dehydration (AIII).

Nutritional supplementation for malnourished patients (AIII).

Immune reconstitution with ART may result in fewer relapses (AIII).

Abbreviations: ACTG = AIDS Clinical Trials Group; ART = antiretroviral therapy; ARV = antiretroviral; ATV/r = ritonavir-boosted atazanavir; BID = twice a day; BIW = twice weekly; BOC = boceprevir; CD4 = CD4 T lymphocyte cell; CDC = The Centers for Disease Control and Prevention; CFU = colony-forming unit; CNS = central nervous system; CSF = cerebrospinal fluid; CYP3A4 = Cytochrome P450 3A4; ddI = didanosine; DOT = directly-observed therapy; DS = double strength; EFV = efavirenz; EMB = ethambutol; g = gram; G6PD = Glucose-6-phosphate dehydrogenase; GI = gastrointestinal; ICP = intracranial pressure; ICU = intensive care unit; IM = intramuscular; IND = investigational new drug; INH = isoniazid; IRIS = immune reconstitution inflammatory syndrome; IV = intravenous; LP = lumbar puncture; mg = milligram; mmHg = millimeters of mercury; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NSAID = non-steroidal anti-inflammatory drugs; PegIFN = Pegylated interferon; PI = protease inhibitor; PO = oral; PORN = Progressive Outer Retinal Necrosis; PZA = pyrazinamide; qAM = every morning; QID = four times a day; q(n)h = every “n” hours; qPM = every evening; RBV = ribavirin; RFB = rifabutin; RIF = rifampin; SQ = subcutaneous; SS = single strength; TID = three times daily; TVR = telaprevir; TMP-SMX = trimethoprim-sulfamethoxazole; ZDV = zidovudine

a Refer to http://www.daraprimdirect.com for information regarding how to access pyrimethamine

Evidence Rating:
Strength of Recommendation:
A: Strong recommendation for the statement
B: Moderate recommendation for the statement
C: Optional recommendation for the statement

Quality of Evidence for the Recommendation:
I: One or more randomized trials with clinical outcomes and/or validated laboratory endpoints
II: One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes
III: Expert opinion

In cases where there are no data for the prevention or treatment of an OI based on studies conducted in HIV-infected populations, but data derived from HIV-uninfected patients exist that can plausibly guide management decisions for patients with HIV/AIDS, the data will be rated as III but will be assigned recommendations of A, B, C depending on the strength of recommendation.

[Source 14]

Table 4. Summary of Pre-Clinical and Human Data on, and Indications for, Opportunistic Infection Drugs During Pregnancy

DrugFDA Category
Pertinent Animal Reproductive and Human Pregnancy DataRecommended Use During Pregnancy
Acyclovir
BNo teratogenicity in mice, rats, rabbits at human levels. Large experience in pregnancy (>700 first-trimester exposures reported to registry); well-tolerated.
Treatment of frequent or severe symptomatic herpes outbreaks or varicella
Adefovir
CNo increase in malformations at 23 times (rats) and 40 times (rabbits) human dose. Limited experience with human use in pregnancy.
Not recommended because of limited data in pregnancy. Report exposures during pregnancy to Antiretroviral Pregnancy Registry: http://www.APRegistry.com
Albendazole
CEmbryotoxic and teratogenic (skeletal malformations) in rats and rabbits, but not in mice or cows. Limited experience in human pregnancy.
Not recommended, especially in first trimester. Primary therapy for microsporidiosis in pregnancy should be ART.
Amikacin
CNot teratogenic in mice, rats, rabbits. Theoretical risk of ototoxicity in fetus; reported with streptomycin but not amikacin.
Drug-resistant TB, severe MAC infections
Amoxicillin, amox./
clavulanate, ampicillin/
sulbactam
BNot teratogenic in animals. Large experience in human pregnancy does not suggest an increase in adverse events.
Susceptible bacterial infections
Amphotericin B
BNot teratogenic in animals or in human experience. Preferred over azole antifungals in first trimester if similar efficacy expected.
Documented invasive fungal disease
Antimonials, pentavalent (stibogluconate, meglumine)
Not FDA approved
Antimony not teratogenic in rats, chicks, sheep. Three cases reported of use in human pregnancy in second trimester with good outcome. Labeled as contraindicated in pregnancy.
Therapy of visceral leishmaniasis not responsive to amphotericin B or pentamidine
Artesunate, artemether, artemether/
lumefantrine
CEmbryotoxicity, cardiovascular and skeletal anomalies in rats and rabbits. Embryotoxic in monkeys. Human experience, primarily in the second and third trimesters, has not identified increased adverse events.
Recommended by WHO as first-line therapy in second/third trimester for P. falciparum and severe malaria. Pending more data, use for malaria in first trimester only if other drugs not available or have failed. Report cases of exposure to WHO Anti-malarial Pregnancy Exposure Registry when available.
Atovaquone
CNot teratogenic in rats or rabbits, limited human experience
Alternate agent for PCP, Toxoplasma gondii, malaria infections
Azithromycin
BNot teratogenic in animals. Moderate experience with use in human pregnancy does not suggest adverse events.
Preferred agent for MAC prophylaxis or treatment (with ethambutol), Chlamydia trachomatis infection in pregnancy.
Aztreonam
BNot teratogenic in rats, rabbits. Limited human experience, but other beta-lactam antibiotics have not been associated with adverse pregnancy outcomes.
Susceptible bacterial infections
BedaquilineBNot teratogenic in rats, rabbits. No experience in human pregnancy. Multidrug resistant TB when effective treatment regimen can not otherwise be provided.
Benznidazole
Not FDA approved No animal studies. Increase in chromosomal aberrations in children with treatment; uncertain significance. No human pregnancy data.
Not indicated for chronic T. cruzi in pregnancy. Seek expert consultation if acute or symptomatic infection in pregnancy requiring treatment.
Boceprevir
BNot teratogenic in rats, rabbits. No human pregnancy data.
Treatment of HCV currently generally not indicated in pregnancy.
Capreomycin
CIncrease in skeletal variants in rats. Limited experience in human pregnancy; theoretical risk of fetal ototoxicity.
Drug-resistant TB
Caspofungin
CEmbryotoxic, skeletal defects in rats, rabbits. No experience with human use.
Invasive Candida or Aspergillus infections refractory to amphotericin and azoles
Cephalosporins
BNot teratogenic in animals. Large experience in human pregnancy has not suggested increase in adverse outcomes.
Bacterial infections; alternate treatment for MAC
Chloroquine
CAssociated with anophthalmia, micro-ophthalmia at fetotoxic doses in animals. Not associated with increased risk in human pregnancy at doses used for malaria.
Drug of choice for malaria prophylaxis and treatment of sensitive species in pregnancy.
Cidofovir
CEmbryotoxic and teratogenic (meningocele, skeletal abnormalities) in rats and rabbits. No experience in human pregnancy.
Not recommended
Ciprofloxacin, other quinolones
CArthropathy in immature animals; not embryotoxic or teratogenic in mice, rats, rabbits, or monkeys. More than 1100 cases of quinolone use in human pregnancy have not been associated with arthropathy or birth defects.
Severe MAC infections; multidrug resistant TB, anthrax, bacterial infections
Clarithromycin
CCardiovascular defects noted in one strain of rats and cleft palate in mice at high doses, not teratogenic in rabbits or monkeys. Two human studies, each with >100 first-trimester exposures, did not show increase in defects but one study found an increase in spontaneous abortion.
Treatment or secondary MAC prophylaxis, if other choices exhausted
Clindamycin
BNo concerns specific to pregnancy in animal or human studies.
Treatment of anaerobic bacterial infections and used with quinine for chloroquine-resistant malaria; alternate agent for secondary prophylaxis of Toxoplasma encephalitis
Clofazimine
CNot teratogenic in mice, rats, or rabbits. Limited experience reported (19 cases); no anomalies noted but red-brown skin discoloration reported in several infants exposed throughout pregnancy.
No indications.
Clotrimazole troches
CNot teratogenic in animals at exposures expected from treatment of oral or vaginal Candida. No increase in adverse pregnancy outcomes with vaginal use.
Oral or vaginal Candida infections and prophylaxis
Cycloserine
CNot teratogenic in rats. No data available from human studies.
Drug-resistant TB
Dapsone
CNo animal data. Limited human experience does not suggest teratogenicity; might displace bound bilirubin in the neonate, increasing the risk of kernicterus. Case reports of hemolytic anemia in fetus/infant with maternal treatment.
Alternate choice for primary or secondary PCP prophylaxis
Diphenoxylate
CLimited animal and human data do not indicate teratogenicity.
Symptomatic treatment of diarrhea
Doxycycline, other tetracyclines
DRisk of hepatic toxicity increased with tetracyclines in pregnancy; staining of fetal bones and teeth contraindicates use in pregnancy.
No indications
Emtricitabine
BNo concerns in pregnancy from limited animal and human data.
As part of fully suppressive combination antiretroviral regimen for treatment of HIV, HBV. Report exposures during pregnancy to Antiretroviral Pregnancy Registry: http://www.APRegistry.com.
Entecavir
CAnimal data do not suggest teratogenicity at human doses; limited experience in human pregnancy.
Not recommended because of limited data in pregnancy. Use as part of fully suppressive ARV regimen with ARV agents active against both HIV and HBV. Report exposures during pregnancy to Antiretroviral Pregnancy Registry: http://www.APRegistry.com.
Erythromycin
BHepatotoxicity with erythromycin estolate in pregnancy; other forms acceptable; no evidence of teratogenicity
Bacterial and chlamydial infections
Ethambutol
BTeratogenic, at high doses, in mice, rats, rabbits. No evidence of teratogenicity in 320 cases of human use for treatment of TB.
Active TB and MAC treatment; avoid in first trimester if possible
Ethionamide
CIncreased rate of defects (omphalocele, exencephaly, cleft palate) in rats, mice, and rabbits with high doses; not seen with usual human doses. Limited human data; case reports of CNS defects.
Active TB; avoid in first trimester if possible
Famciclovir
BNo evidence of teratogenicity in rats or rabbits, limited human experience.
Recurrent genital herpes and primary varicella infection. Report exposures during pregnancy to the Famvir Pregnancy Registry (1-888-669-6682).
Fluconazole
CAbnormal ossification, structural defects in rats, mice at high doses. Case reports of rare pattern of craniofacial, skeletal and other abnormalities in five infants born to four women with prolonged exposure during pregnancy; no increase in defects seen in several series after single dose treatment.
Single dose may be used for treatment of vaginal Candida though topical therapy preferred. Not recommended for prophylaxis during early pregnancy. Can be used for invasive fungal infections after first trimester; amphotericin B preferred in first trimester if similar efficacy expected.
Flucytosine
CFacial clefts and skeletal defects in rats; cleft palate in mice, no defects in rabbits. No reports of use in first trimester of human pregnancy; may be metabolized to 5-fluorouracil, which is teratogenic in animals and possibly in humans.
Use after first trimester if indicated for life-threatening fungal infections.
Foscarnet
CSkeletal variants in rats, rabbits and hypoplastic dental enamel in rats. Single case report of use in human pregnancy in third trimester.
Alternate agent for treatment or secondary prophylaxis of life-threatening or sight-threatening CMV infection.
Fumagillin
Not FDA approvedCaused complete litter destruction or growth retardation in rats, depending on when administered. No data in human pregnancy.
Topical solution can be used for ocular microsporidial infections.
Ganciclovir, valganciclovir
CEmbryotoxic in rabbits and mice; teratogenic in rabbits (cleft palate, anophthalmia, aplastic kidney and pancreas, hydrocephalus). Case reports of safe use in human pregnancy after transplants, treatment of fetal CMV.
Treatment or secondary prophylaxis of life-threatening or sight-threatening CMV infection. Preferred agent for therapy in children.
Imipenem, meropenem
C/BNot teratogenic in animals; limited human experience.
Serious bacterial infections
Imiquimod
BNot teratogenic in rats and rabbits; 8 case reports of human use, only 2 in first trimester.
Because of limited experience, other treatment modalities such as cryotherapy or trichloracetic acid recommended for wart treatment during pregnancy.
Influenza vaccine
CNot teratogenic. Live vaccines, including intranasal influenza vaccine, are contraindicated in pregnancy.
All pregnant women should receive injectable influenza vaccine because of the increased risk of complications of influenza during pregnancy. Ideally, HIV-infected women should be on ART before vaccination to limit potential increases in HIV RNA levels with immunization.
Interferons
(alfa, beta, gamma)
CAbortifacient at high doses in monkeys, mice; not teratogenic in monkeys, mice, rats, or rabbits. Approximately 30 cases of use of interferon-alfa in pregnancy reported; 14 in first trimester without increase in anomalies; possible increased risk of intrauterine growth retardation.
Not indicated. Treatment of HCV currently generally not recommended in pregnancy.
Isoniazid
CNot teratogenic in animals. Possible increased risk of hepatotoxicity during pregnancy; prophylactic pyridoxine, 50 mg/day, should be given to prevent maternal and fetal neurotoxicity.
Active TB; prophylaxis for exposure or skin test conversion
Itraconazole
CTeratogenic in rats and mice at high doses. Case reports of craniofacial, skeletal abnormalities in humans with prolonged fluconazole exposure during pregnancy; no increase in defect rate noted among over 300 infants born after first-trimester itraconazole exposure.
Only for documented systemic fungal disease, not prophylaxis. Consider using amphotericin B in first trimester if similar efficacy expected.
Kanamycin
DAssociated with club feet in mice, inner ear changes in multiple species. Hearing loss in 2.3% of 391 children after long-term in utero therapy.
Drug-resistant TB
Ketoconazole
CTeratogenic in rats, increased fetal death in mice, rabbits. Inhibits androgen and corticosteroid synthesis; may impact fetal male genital development; case reports of craniofacial, skeletal abnormalities in humans with prolonged fluconazole exposure during pregnancy.
None
Lamivudine
CNot teratogenic in animals. No evidence of teratogenicity with >3700 first-trimester exposures reported to Antiretroviral Pregnancy Registry.
HIV and HBV therapy, only as part of a fully suppressive combination ARV regimen. Report exposures to Antiretroviral Pregnancy Registry: http://www.APRegistry.com.
Ledipasvir/sofosbuvirBNo evidence of teratogenicity in rats or rabbits. No experience in human pregnancy.Treatment of hepatitis C generally not indicated in pregnancy.
Leucovorin
(folinic acid)
CPrevents birth defects of valproic acid, methotrexate, phenytoin, aminopterin in animal models. No evidence of harm in human pregnancies.
Use with pyrimethamine if use of pyrimethamine cannot be avoided.
Linezolid
CNot teratogenic in animals. Decreased fetal weight and neonatal survival at ~ human exposures, possibly related to maternal toxicity. Limited human experience.
Serious bacterial infections
Loperamide
BNot teratogenic in animals. No increase in birth defects among infants born to 89 women with first-trimester exposure in one study; another study suggests a possible increased risk of hypospadias with first-trimester exposure, but confirmation required.
Symptomatic treatment of diarrhea after the first trimester
Mefloquine
CAnimal data and human data do not suggest an increased risk of birth defects, but miscarriage and stillbirth may be increased.
Second-line therapy of chloroquine-resistant malaria in pregnancy, if quinine/clindamycin not available or not tolerated. Weekly as prophylaxis in areas with chloroquine-resistant malaria.
Meglumine 
Not FDA approvedSee Antimonials, pentavalent
 
Metronidazole
BMultiple studies do not indicate teratogenicity. Studies on several hundred women with first-trimester exposure found no increase in birth defects.
Anaerobic bacterial infections, bacterial vaginosis, trichomoniasis, giardiasis, amebiasis
Micafungin
CTeratogenic in rabbits; no human experience.
Not recommended
Miltefosine
Not FDA approvedEmbryotoxic in rats, rabbits; teratogenic in rats. No experience with human use.
Not recommended
Nifurtimox
Not FDA approvedNot teratogenic in mice and rats. Increased chromosomal aberrations in children receiving treatment; uncertain significance. No experience in human pregnancy.
Not indicated in chronic infection; seek expert consultation if acute infection or symptomatic reactivation of T. cruzi in pregnancy.
Nitazoxanide
BNot teratogenic in animals; no human data
Severely symptomatic cryptosporidiosis after the first trimester
Para-amino salicylic acid
(PAS)
COccipital bone defects in one study in rats; not teratogenic in rabbits. Possible increase in limb, ear anomalies in one study with 143 first-trimester exposures; no specific pattern of defects noted, several studies did not find increased risk.
Drug-resistant TB
Paromomycin
CNot teratogenic in mice and rabbits. Limited human experience, but poor oral absorption makes toxicity, teratogenicity unlikely.
Amebic intestinal infections, possibly cryptosporidiosis
Penicillin
BNot teratogenic in multiple animal species. Vast experience with use in human pregnancy does not suggest teratogenicity, other adverse outcomes.
Syphilis, other susceptible bacterial infections
Pentamidine
CEmbryocidal but not teratogenic in rats, rabbits with systemic use. Limited experience with systemic use in pregnancy.
Alternate therapy for PCP and leishmaniasis.
Piperacillin-tazobactam
BNot teratogenic in limited animal studies. Limited experience in pregnancy but penicillins generally considered safe.
Bacterial infections
Pneumococcal vaccine
CNo studies in animal pregnancy. Polysaccharide vaccines generally considered safe in pregnancy. Well-tolerated in third-trimester studies.
Initial or booster dose for prevention of invasive pneumococcal infections. HIV-infected pregnant women should be on ART before vaccination to limit potential increases in HIV RNA levels with immunization.
Podophyllin, podofilox
CIncreased embryonic and fetal deaths in rats, mice but not teratogenic. Case reports of maternal, fetal deaths after use of podophyllin resin in pregnancy; no clear increase in birth defects with first-trimester exposure.
Because alternative treatments for genital warts in pregnancy are available, use not recommended; inadvertent use in early pregnancy is not indication for abortion.
Posaconazole
CEmbryotoxic in rabbits; teratogenic in rats at similar to human exposures. No experience in human pregnancy.
Not recommended
Prednisone
BDose-dependent increased risk of cleft palate in mice, rabbits, hamsters; dose-dependent increase in genital anomalies in mice. Human data inconsistent regarding increased risk of cleft palate. Risk of growth retardation, low birth weight may be increased with chronic use; monitor for hyperglycemia with use in third trimester.
Adjunctive therapy for severe PCP; multiple other non-HIV-related indications
Primaquine
CNo animal data. Limited experience with use in human pregnancy; theoretical risk for hemolytic anemia if fetus has G6PD deficiency.
Alternate therapy for PCP, chloroquine-resistant malaria
Proguanil
CNot teratogenic in animals. Widely used in malaria-endemic areas with no clear increase in adverse outcomes.
Alternate therapy and prophylaxis of P. falciparum malaria
Pyrazinamide
CNot teratogenic in rats, mice. Limited experience with use in human pregnancy.
Active TB
Pyrimethamine
CTeratogenic in mice, rats, hamsters (cleft palate, neural tube defects, and limb anomalies). Limited human data have not suggested an increased risk of birth defects; because folate antagonist, use with leucovorin.
Treatment and secondary prophylaxis of toxoplasmic encephalitis; alternate treatment of PCP
Quinidine gluconate
CGenerally considered safe in pregnancy; high doses associated with preterm labor. One case of fetal 8th nerve damage reported.
Alternate treatment of malaria, control of fetal arrhythmias
Quinine sulfate
CHigh doses, often taken as an abortifacient, have been associated with birth defects, especially deafness, in humans and animals. Therapeutic doses have not been associated with an increased risk of defects in humans or animals. Monitor for hypoglycemia.
Treatment of chloroquine-resistant malaria
Ribavirin
XDose-dependent risk of multiple defects (craniofacial, central nervous system, skeletal, anophthalmia) in rats, mice, hamsters starting at below human doses. Reports of treatment during second half of pregnancy in nine women without incident; first 49 cases in registry did not suggest increased risk, but limited data.
Contraindicated in early pregnancy; no clear indications in pregnancy. Report exposures during pregnancy to Ribavirin Pregnancy Registry at (800) 593-2214 or www.ribavirinpregnancyregistry.com
Rifabutin
BNot teratogenic in rats and rabbits; no specific concerns for human pregnancy.
Treatment or prophylaxis of MAC, active TB
Rifampin
CTeratogenic at high doses in mice (cleft palate) and rats (spina bifida) but not in rabbits. No clear teratogenicity in humans.
Active TB
SimeprevirCDecreased fetal weights and increased skeletal variants in mice at 4x human exposure. Increased deaths and decreased fetal and neonatal growth and developmental delay after in utero exposure in rats. No experience in human pregnancy. Treatment of HCV currently generally not recommended in pregnancy. 
Sinecatechin ointmentCNo evidence of teratogenicity in rats and rabbits after oral or intravaginal dosing. No experience in human pregnancy.Not recommended based on lack of data.
SofosbuvirBNo evidence of teratogenicity in rats or rabbits. No experience in human pregnancy. Treatment of HCV generally not indicated in pregnancy. Regimens including ribavirin and interferon are contraindicated in pregnancy.
Streptomycin
DNo teratogenicity in mice, rats, guinea pigs. Possible increased risk of deafness and VIII nerve damage; no evidence of other defects.
Alternate therapy for active TB
Sulfadiazine
BSulfonamides teratogenic in some animal studies. No clear teratogenicity in humans; potential for increased jaundice, kernicterus if used near delivery.
Secondary prophylaxis of toxoplasmic encephalitis
Telaprevir
BNot teratogenic in mice, rats. No human pregnancy data.
Treatment of HCV currently generally not indicated in pregnancy.
Telbivudine
BNot teratogenic in rats, rabbits. Limited experience in human pregnancy.
Not recommended because of limited data in pregnancy. Use as part of fully suppressive antiretroviral regimen with antiretroviral agents active against both HIV and hepatitis B. Report exposures during pregnancy to Antiretroviral Pregnancy Registry: http://www.APRegistry.com.
Tenofovir
BNo evidence of birth defects in rats, rabbits, or monkeys at high doses; chronic administration in immature animals of multiple species at 6–50 times human doses has led to dose-specific bone changes ranging from decreased mineral density to severe osteomalacia and fractures. Clinical studies in humans (particularly children) show bone demineralization with chronic use; clinical significance unknown. No evidence of increased birth defects in nearly 2000 first-trimester exposures in women.
Component of fully suppressive antiretroviral regimen in pregnant women. Report exposures during pregnancy to Antiretroviral Pregnancy Registry: http://www.APRegistry.com.
Trichloracetic acid, bichloracetic acid
Not ratedNo studies. Used topically so no systemic absorption expected.
Topical therapy of non-cervical genital warts
Trifluridine
CNot teratogenic in rats, rabbits. Minimal systemic absorption expected with topical ocular use.
Topical agent for treatment of ocular herpes infections
Trimethoprim-sulfamethoxazole
CTeratogenic in rats and mice. Possible increase in congenital cardiac defects, facial clefts, neural tube and urinary defects with first-trimester use. Unclear if higher levels of folate supplementation lower risk. Theoretical risk of elevated bilirubin in the neonate if used near delivery.
Therapy of PCP during pregnancy. Primary and secondary PCP prophylaxis in the second/third trimester; consider aerosolized pentamidine in first trimester. Recommend fetal ultrasound at 18–20 weeks after first-trimester exposure.
Valacyclovir
BNot teratogenic in mice, rats, and rabbits. Experience with valacyclovir in pregnancy limited; prodrug of acyclovir, which is considered safe for use in pregnancy.
Treatment of HSV and varicella infections in pregnancy
Vancomycin
CNot teratogenic in rats, rabbits. Limited human experience.
Serious bacterial infections
Voriconazole
DEmbryotoxic in rats, rabbits. Teratogenic in rats (cleft palate, hydronephrosis, and ossification defects). No experience with human use.
Not recommended
Key to Acronyms: ART = antiretroviral therapy; ARV = antiretroviral; CMV = cytomegalovirus; CNS = central nervous system; FDA = Food and Drug Administration; G6PD = Glucose-6-phosphate dehydrogenase; HBV = hepatitis B virus; HCV = hepatitis C virus; HSV = herpes simplex virus; MAC = Mycobacterium avium complex; PCP = Pneumocystis pneumonia; TB = tuberculosis; VIII nerve = vestibulocochlear nerve; WHO = World Health Organization
[Source 15]
  1. What is an Opportunistic Infection? https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/26/86/what-is-an-opportunistic-infection-[]
  2. Buchacz K, Lau B, Jing Y, et al. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis. 2016;214(6):862-872.[]
  3. Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDS. 2014;28(3):128-135.[]
  4. Berry SA, Fleishman JA, Moore RD, Gebo KA, Network HIVR. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr. 2012;59(4):368-375.[]
  5. Centers for Disease Control and Prevention. Table 8 in Estimated HIV incidence and prevalence in the United States, 2010–2015. HIV Surveillance Supplemental Report. 2018;23(1). https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-23-1.pdf[]
  6. Dailey AF, Hoots BE, Hall HI, et al. Vital Signs: Human Immunodeficiency Virus Testing and Diagnosis Delays – United States. MMWR Morb Mortal Wkly Rep. 2017;66(47):1300-1306.[]
  7. Centers for Disease Control and Prevention. Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 Dependent Areas, 2015. HIV Surveillance Supplemental Report. 2017;22(2). https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-22-2.pdf[]
  8. HIV Continuum of Care, U.S., 2014, Overall and by Age, Race/Ethnicity, Transmission Route and Sex [press release]. July 27, 2017 2017.[]
  9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Limitations to Treatment Safety and Efficacy. In: Department of Health and Human Services, ed. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.2017.[]
  10. Vanhems P, Voisin L, Gayet-Ageron A, et al. The incidence of herpes zoster is less likely than other opportunistic infections to be reduced by highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2005;38(1):111-113.[]
  11. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet. 2005;365(9455):233-240.[]
  12. AIDS and Opportunistic Infections. https://www.cdc.gov/hiv/basics/livingwithhiv/opportunisticinfections.html[]
  13. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/354/primary-prophylaxis[]
  14. Table 2. Treatment of AIDS-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy). https://aidsinfo.nih.gov/guidelines/htmltables/4/6262[]
  15. Table 8. Summary of Pre-Clinical and Human Data on, and Indications for, Opportunistic Infection Drugs During Pregnancy. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/361/oi-drugs-in-pregnancy[]
read more
Health topics

Postmenopausal

postmenopausal

What is postmenopausal

Post menopause means the period of life after the menopause. Menopause is the time when your menstrual periods stop permanently and you can no longer get pregnant. You have reached menopause only after it has been a full year since your last period. This means you have not had any vaginal bleeding, including spotting, for 12 months in a row. Menopause is a normal part of a woman’s life. It is sometimes called “the change of life.” Menopause does not happen all at once. As your body transitions to menopause over several years, you may have menopause symptoms and irregular periods. The average age for menopause in the United States is 52.

Some people call the time leading up to a woman’s last period menopause. This time actually is the transition to menopause, better known as perimenopause. Perimenopause means “around menopause.” After menopause, your body makes much less of the hormones estrogen and progesterone. Very low estrogen levels after menopause can affect your health and cause symptoms such as hot flashes. You can take steps to protect your health and relieve your symptoms.

Menopause happens when you have gone 12 months in a row without a period. The average age of menopause in the United States is 52. The range for women is usually between 45 and 58 1. One way to tell when you might go through menopause is the age your mother went through it 2.

Menopause may happen earlier if you:

  • Never had children. Pregnancy, especially more than one pregnancy, may delay menopause 3
  • Smoke. Studies show smoking can cause you to start menopause up to two years earlier than women who don’t smoke 4

Certain health problems can also cause you to start menopause earlier.

Menopause usually happens on its own. However, you may enter menopause earlier than you normally would if you have had chemotherapy or surgery to remove both ovaries.

Symptoms of menopause may begin suddenly and be very noticeable, or they may be very mild at first. Symptoms may happen most of the time once they begin, or they may happen only once in a while. Some women notice changes in many areas. Some menopausal symptoms, such as moodiness, are similar to symptoms of premenstrual syndrome (PMS). Others may be new to you. For example:

  • Your menstrual periods may not come as regularly as before. They also might last longer or be shorter. You might skip some months. Periods might stop for a few months and then start up again.
  • Your periods might be heavier or lighter than before.
  • You might have hot flashes and problems sleeping.
  • You might experience mood swings or be irritable.
  • You might experience vaginal dryness. Sex may be uncomfortable or painful.
  • You may have less interest in sex. It may take longer for you to get aroused.

Other possible changes are not as noticeable. For example, you might begin to lose bone density because you have less estrogen. This can lead to osteoporosis, a condition that causes bones to become weak and break easily. Changing estrogen levels can also raise cholesterol levels and increase your risk for heart disease and stroke.

Talk to your doctor about possible treatment for your menopause symptoms if they bother you.

What happens after menopause?

After menopause you will no longer be able to get pregnant and you will no longer get a period. If you have any type of vaginal bleeding after menopause, you should see a doctor as soon as possible. Vaginal bleeding after menopause is not normal and can mean that you have a serious health problem.

You may experience any of the following after menopause:

  • Low hormone levels. With menopause, your ovaries make very little of the hormones estrogen and progesterone. Because of changing hormone levels, you may develop certain health risks, including osteoporosis, heart disease, and stroke.
  • Menopause symptoms instead of period problems. After menopause, most women get relief from period problems or menopause symptoms. However, you may still experience symptoms such as hot flashes because of changing estrogen levels. One recent study found that hot flashes can continue for up to 14 years after menopause 5
  • Vaginal dryness. Vaginal dryness may be more common post-menopause. Learn more about treatments for vaginal dryness.

Postmenopausal health problems

After menopause, your ovaries make very little estrogen. Women who have gone through menopause have very low estrogen levels. Low levels of estrogen and progesterone raise your risk for certain health problems after menopause. Other health problems may happen naturally as you age.

Examples of common health problems in the years after menopause include:

  • Heart disease. Before age 55, women have a lower risk of heart disease than men. Estrogen helps keep blood vessels relaxed and open and helps the body maintain a healthy balance of good and bad cholesterol. Without estrogen, cholesterol may start building up on artery walls leading to the heart. By age 70, women have about the same risk for heart disease as men of the same age.
  • Stroke. Your risk for stroke doubles every decade after age 55 6. The lower levels of estrogen in your body may play a role in cholesterol build-up on artery walls leading to the brain.
  • Osteoporosis. Having less estrogen after menopause causes you to lose bone mass much more quickly than you did before, which puts you at risk for osteoporosis. Osteoporosis is a condition that causes your bones to become brittle and weak and break easily. A recent large study found that women who have severe hot flashes and night sweats during the years around menopause usually have more bone loss and are at higher risk for hip fractures than women who do not have severe symptoms 7
  • Lead poisoning. Lead that you are exposed to over your lifetime gets stored in your bones. Because bone begins to break down much more quickly after menopause, that lead is more likely to be released into the blood. Older women can have blood lead levels 30% higher than before they reached menopause. This lead increases your risk for high blood pressure and atherosclerosis (sometimes called hardening of the arteries). This lead in your blood can also cause your kidneys to not work as well. It can also cause symptoms similar to dementia, affecting your memory and ability to think 8
  • Urinary incontinence. About half of postmenopausal women have trouble holding in their urine 1. Lower estrogen levels may weaken the urethra. Learn about treatment options for incontinence.
  • Oral issues. Dry mouth and an increased risk for cavities are more common after menopause. Learn more about oral health.

Please speak to your doctor if you are concerned.

Does hormone therapy during menopause prevent these health problems?

No. Menopausal hormone therapy is medicine to help relieve your menopause symptoms, such as hot flashes and vaginal dryness. Menopausal hormone therapy may actually raise your risk for blood clots, stroke, and some cancers and does not help prevent heart disease or dementia.

What screenings do I need after menopause?

All women need regular checkups and screening tests throughout their lives. Most women can help take care of their health with:

  • Regular mammograms after age 50 through age 75
  • Regular Pap tests, even after menopause. You should get a Pap test and HPV test together every five years if you have a cervix, until you are 65 and have had three clear tests in a row.
  • Regular height measurements to detect loss of height due to bone loss
  • Blood, urine, and other tests to screen for risk of diabetes and heart disease
  • Blood pressure, cholesterol, and other tests your doctor recommends

Ask your doctor or nurse about flu shots and other vaccines. Besides the flu shot, vaccinations are available for pneumonia, shingles, and other diseases.

Your doctor or nurse might also recommend other tests, depending on your health. For example, you might need to see a specialist for some specific problems, like urinary incontinence.

How can I stay healthy during and after menopause?

There are many important steps you can take to build your health in the years around menopause.

  • Quit smoking. Quitting smoking is the most important step you can take to be healthier. Smoking hurts your health in many ways, including by damaging your bones and causing heart disease and as many as 12 types of cancer in women.5,6 Stay away from secondhand smoke and get help quitting if you need it.
  • Be active. Getting at least 30 minutes of physical activity on most days of the week is one of the best ways you can be healthier. Physical activity can help your bones, heart, and mood. Exercise doesn’t have to be complicated. Brisk walking and regular household chores are good for your health. Ask your doctor about what activities are right for you. Aim to do:
    • At least 2 hours and 30 minutes a week of moderate aerobic physical activity or 1 hour and 15 minutes of vigorous aerobic activity or some combination of the two
    • Exercises that build muscle strength on two days each week
  • Eat well. Getting vitamins, minerals, fiber, and other essential nutrients is just as important as when you were younger. But older women usually need fewer calories for energy.
  • Talk to your doctor or nurse about dietary supplements.
    • Women older than 50 need 2.4 micrograms of vitamin B12 and 1.5 milligrams of vitamin B6 each day. Ask your doctor or nurse if you need a vitamin supplement.
    • After menopause, calcium needs go up to maintain bone health. Doctors recommend that women 51 and older get 1,200 milligrams of calcium each day. Vitamin D also is important to bone health. Doctors also recommend that women 51 to 70 get 600 international units (IU) of vitamin D each day and women ages 71 and older get 800 IU of vitamin D each day. Ask your doctor or nurse if you need a calcium supplement or if you need more vitamin D.
  • Practice safe sex. After menopause, you can’t get pregnant. But you can still get a sexually transmitted infection (STI, or STD). Condoms are the best way to prevent STIs when you have sex. After menopause the vagina may be drier and thinner, leading to small cuts or tears during sex. Vaginal cuts or tears put you at higher risk for STIs.

Will I gain weight after menopause?

Maybe. Many women gain an average of 5 pounds after menopause. Lower estrogen levels may play a role in weight gain after menopause. But weight gain may be caused by your metabolism slowing down as you age. You may also not eat as healthy or be as active as when you were younger. You also lose muscle mass as you age (muscle burns more calories at rest than other types of tissue in the body).

Weight gain can raise your risk for high blood pressure, cholesterol, diabetes, heart attack, and stroke. The risk is greater if you are already overweight or are not active or eating healthy.

The best way to lose weight, if you are overweight or obese, is to eat fewer calories each day. Exercise or physical activity is also important for good health, but works better to keep weight off than it does to help you lose weight. Researchers think this might be because people who are physically active are usually hungrier. Eating healthy and getting at least 30 minutes of exercise on most days is the best way to keep a healthy weight.

Postmenopausal vaginal bleeding

Menopause is usually diagnosed in women over 45 who haven’t had a period for more than a year. Any bleeding from the vagina after this needs to be checked by a doctor.

Postmenopausal bleeding

See a doctor if you have postmenopausal bleeding, even if:

  • it’s only happened once
  • there’s only a small amount of blood, spotting, or pink or brown discharge
  • you don’t have any other symptoms
  • you’re not sure if it’s blood

Postmenopausal bleeding isn’t usually serious, but can be a sign of cancer. Cancer is easier to treat if it’s found early.

A doctor, will offer you tests to help find out what’s causing postmenopausal bleeding and plan any necessary treatment.

The tests may include:

  • a small device being placed in your vagina to scan for any problems (vaginal ultrasound scan)
  • an examination of your pelvis and vagina
  • a thin, telescope-like camera being passed up your vagina and into your womb to look for any problems (a hysteroscopy) and to take a tissue sample (biopsy) for testing – under local or general anaesthetic

Causes of postmenopausal bleeding

There can be several causes of postmenopausal bleeding.

The most common causes postmenopausal bleeding or spotting are:

  • inflammation and thinning of the vaginal lining (atrophic vaginitis) or womb lining (endometrial atrophy) – caused by lower estrogen levels
  • cervical or womb polyps – growths that are usually non-cancerous
  • a thickened womb lining (endometrial hyperplasia) – this can be caused by hormone replacement therapy (HRT), high levels of estrogen or being overweight, and can lead to womb cancer (cancer of the uterus)

Less commonly, postmenopausal bleeding is caused by cancer.

Treatment for postmenopausal bleeding

Treatment depends on what’s causing your bleeding.

Postmenopausal osteoporosis

Osteoporosis is a disease of the bones that causes bones to become weak and break easily. Osteoporosis affects mostly older women, but prevention starts when you are younger. No matter your age, you can take steps to build bone mass and prevent bone loss. Broken bones from osteoporosis cause serious health problems and disability in older women.

The most common injuries in people with osteoporosis are:

  • wrist fractures
  • hip fractures
  • fractures of the spinal bones (vertebrae)

However, they can also occur in other bones, such as in the arm or pelvis. Sometimes a cough or sneeze can cause a rib fracture or the partial collapse of one of the bones of the spine.

Osteoporosis isn’t usually painful until a fracture occurs, but spinal fractures are a common cause of long-term (chronic) pain.

Although a fracture is the first sign of osteoporosis, some older people develop the characteristic stooped (bent forward) posture. It happens when the bones in the spine have fractured, making it difficult to support the weight of the body.

Signs and Symptoms of Osteoporosis

Patients with osteoporosis are asymptomatic unless a fracture has occurred. Sometimes there are obvious signs that a person has osteoporosis – for example they may ”shrink” a little and develop a stooped posture. But often the first sign that someone has osteoporosis is when they break a bone, sometimes without knowing how or why it happened. This kind of break is called a “spontaneous fracture.” When bone mass is lost the risk of breaking a bone (fractures) is higher. Osteoporosis that has already caused a fracture is referred to as “established” osteoporosis.

The bones of the spinal column (vertebrae) are the most likely to break or “collapse” in someone who has osteoporosis. Sometimes this will cause back pain, but most people do not notice anything.

Broken vertebrae are one reason why many older people stoop over and develop what is often called a “dowager’s hump” at the top of their spine.

Osteoporosis also commonly affects the wrist, the upper arm and the femur (thigh bone).

Nonvertebral fractures are typically symptomatic, but about two thirds of vertebral compression fractures are asymptomatic (although patients may have underlying chronic back pain due to other causes such as osteoarthritis). A vertebral compression fracture that is symptomatic begins with acute onset of pain that usually does not radiate, is aggravated by weight bearing, may be accompanied by point spinal tenderness, and typically begins to subside in 1 wk. However, residual pain may last for months or be constant.

Multiple thoracic compression fractures eventually cause dorsal kyphosis, with exaggerated cervical lordosis (dowager’s hump). Abnormal stress on the spinal muscles and ligaments may cause chronic, dull, aching pain, particularly in the lower back. Patients may have shortness of breath due to the reduced intrathoracic volume and/or abdominal discomfort due to the compression of the abdominal cavity as the rib cage approaches the pelvis.

Causes of osteoporosis

Losing bone is a normal part of the ageing process, but some people lose bone density much faster than normal. This can lead to osteoporosis and an increased risk of fractures.

Women also lose bone rapidly in the first few years after the menopause (when monthly periods stop and the ovaries stop producing an egg). Women are more at risk of osteoporosis than men, particularly if the menopause begins early (before the age of 45).

Many other factors can also increase the risk of developing osteoporosis, including:

  • long-term use of high-dose oral corticosteroids
  • other medical conditions – such as inflammatory conditions, hormone-related conditions, or malabsorption problems
  • a family history of osteoporosis – particularly history of a hip fracture in a parent
  • long-term use of certain medications which can affect bone strength or hormone levels
  • having a low body mass index (BMI)
  • heavy drinking and smoking

Preventing osteoporosis

Your genes are responsible for determining your height and the strength of your skeleton, but lifestyle factors such as diet and exercise influence how healthy your bones are.

If you’re at risk of developing osteoporosis, you should take steps to help keep your bones healthy. This may include:

  • taking regular exercise
  • healthy eating – including foods rich in calcium and vitamin D
  • taking a daily supplement containing 10 micrograms (mcg) of vitamin D
  • making lifestyle changes – such as:
    • quitting smoking – smoking is associated with an increased risk of osteoporosis
    • limiting your alcohol intake – it’s also important to avoid binge drinking

Regular exercise

Regular exercise is essential. Adults aged 19 to 64 should do at least 150 minutes (2 hours and 30 minutes) of moderate-intensity aerobic activity, such as cycling or fast walking, every week.

Weight-bearing exercise and resistance exercise are particularly important for improving bone density and helping to prevent osteoporosis.

As well as aerobic exercise, adults aged 19 to 64 should also do muscle-strengthening activities on two or more days a week by working all the major muscle groups, including the legs, hips, back, abdomen, chest, arms and shoulders.

If you’ve been diagnosed with osteoporosis, it’s a good idea to talk to your doctor or health specialist before starting a new exercise programme to make sure it’s right for you.

Physical activity guidelines for older adults aged 65 and over

Adults aged 65 or older who are generally fit and have no health conditions that limit their mobility should try to be active daily.

You should do:

  • at least 150 minutes of moderate aerobic activity such as cycling or walking every week and
  • strength exercises on 2 or more days a week that work all the major muscles (legs, hips, back, abdomen, chest, shoulders and arms)

Or

  • 75 minutes of vigorous aerobic activity such as running or a game of singles tennis every week and
  • strength exercises on 2 or more days a week that work all the major muscles (legs, hips, back, abdomen, chest, shoulders and arms)

Or

  • a mix of moderate and vigorous aerobic activity every week (for example, two 30-minute runs plus 30 minutes of brisk walking equates to 150 minutes of moderate aerobic activity) and
  • strength exercises on 2 or more days a week that work all the major muscles (legs, hips, back, abdomen, chest, shoulders and arms)

A general rule of thumb is that 1 minute of vigorous activity provides the same health benefits as 2 minutes of moderate activity.

You should also try to break up long periods of sitting with light activity, as sedentary behaviour is now considered an independent risk factor for ill health, no matter how much exercise you do.

Older adults at risk of falls, such as people with weak legs, poor balance and some medical conditions, should do exercises to improve balance and co-ordination on at least 2 days a week. Examples include yoga, tai chi and dancing.

What counts as moderate aerobic activity?

Examples of activities that require moderate effort for most people include:

  • walking
  • water aerobics
  • ballroom and line dancing
  • riding a bike on level ground or with few hills
  • playing doubles tennis
  • pushing a lawn mower
  • canoeing
  • volleyball

Moderate activity will raise your heart rate and make you breathe faster and feel warmer.

One way to tell if you’re exercising at a moderate level is if you can still talk but can’t sing the words to a song.

Daily chores such as shopping, cooking or housework don’t count towards your 150 minutes because the effort isn’t enough to raise your heart rate.

But this type of activity is still important, as it breaks up periods of sitting.

Weight-bearing exercises

Weight-bearing exercises are exercises where your feet and legs support your weight. High-impact weight-bearing exercises, such as running, skipping, dancing, aerobics, and even jumping up and down on the spot, are all useful ways to strengthen your muscles, ligaments and joints.

When exercising, wear footwear that provides your ankles and feet with adequate support, such as trainers or walking boots.

People over the age of 60 can also benefit from regular weight-bearing exercise. This can include brisk walking, keep-fit classes or a game of tennis. Swimming and cycling aren’t weight-bearing exercises.

Resistance exercises

Resistance exercises use muscle strength, where the action of the tendons pulling on the bones boosts bone strength. Examples include press-ups, weightlifting or using weight equipment at a gym.

If you’ve recently joined a gym or haven’t been for a while, your gym will probably offer you an induction. This involves being shown how to use the equipment and having exercise techniques recommended to you.

Always ask an instructor for help if you’re not sure how to use a piece of gym equipment or how to do a particular exercise.

Healthy eating and vitamin D supplements

Eating a healthy, balanced diet is recommended for everyone. It can help prevent many serious health conditions, including heart disease, diabetes and many forms of cancer, as well as osteoporosis.

Calcium is important for maintaining strong bones. Adults need 700mg a day, which you should be able to get from your daily diet. Calcium-rich foods include:

  • leafy green vegetables
  • dried fruit
  • tofu
  • yogurt

Vitamin D is also important for healthy bones and teeth because it helps your body absorb calcium. All adults should consume 10 micrograms (mcg) of vitamin D a day. Good dietary sources are:

  • oily fish – such as salmon, sardines, herring and mackerel
  • red meat
  • liver
  • egg yolks
  • fortified foods such as most fat spreads and some breakfast cereals
  • dietary supplements.

However, it can be difficult to get enough vitamin D from foods alone. So, all adults should consider taking a daily supplement containing 10mcg of vitamin D.

Get some sunlight

From late March/April to the end of September, sunlight triggers the production of vitamin D, which helps your body absorb calcium.

This process helps strengthen teeth and bones, which in turn helps prevent conditions such as osteoporosis.

Your body creates vitamin D from direct sunlight on your skin when we’re outdoors. From about late March/early April to the end of September, most people should be able to get all the vitamin D they need from sunlight.

You also get some vitamin D from a small number of foods, including oily fish such as salmon, mackerel, herring and sardines, as well as red meat and eggs.

Another source of vitamin D is dietary supplements.

How long should you spend in the sun?

Most people can make enough vitamin D from being out in the sun daily for short periods with their forearms, hands or lower legs uncovered and without sunscreen from late March or early April to the end of September, especially from 11am to 3pm.

It’s not known exactly how much time is needed in the sun to make enough vitamin D to meet the body’s requirements.

This is because there are a number of factors that can affect how vitamin D is made, such as your skin color or how much skin you have exposed.

But you should be careful not to burn in the sun, so take care to cover up or protect your skin with sunscreen before your skin starts to turn red or burn.

People with dark skin, such as those of African, African-Caribbean or south Asian origin, will need to spend longer in the sun to produce the same amount of vitamin D as someone with lighter skin.

How long it takes for your skin to go red or burn varies from person to person.

Your body can’t make vitamin D if you’re sitting indoors by a sunny window because ultraviolet B (UVB) rays (the ones your body needs to make vitamin D) can’t get through the glass.

The longer you stay in the sun, especially for prolonged periods without sun protection, the greater your risk of skin cancer.

If you plan to be out in the sun for long, cover up with suitable clothing, wrap-around sunglasses, seeking shade and applying at least SPF30+ sunscreen.

Winter sunlight

In the US, sunlight doesn’t contain enough UVB radiation in winter (October to early March) for our skin to be able to make vitamin D.

During these months, we rely on getting our vitamin D from food sources (including fortified foods) and supplements.

Using sunbeds isn’t a recommended way of making vitamin D.

How you can find out if you have Osteoporosis

There are tests you can get to find out your bone density. This is related to how strong or fragile your bones are. One test is called dual-energy X-ray absorptiometry (DXA or DEXA). A DXA scan takes X-rays of your bones. Screening tools also can be used to predict the risk of having low bone density or breaking a bone. Talk with your doctor or nurse about this test or tools to assess risk.

  • DXA Scan

Bone density should be measured using dual-energy X-ray absorptiometry (DXA) to screen people at risk, to provide a quantitative measure of bone loss, and to monitor those undergoing treatment 9.

A DXA scan is recommended for the following patients:

  • All women ≥ 65 yr
  • Women between menopause and age 65 who have risk factors, including a family history of osteoporosis, a low body mass index (eg, previously defined as body weight < 127 lb), and use of tobacco and/or drugs with a high risk of bone loss (eg, glucocorticoids)
  • Patients (men and women) of any age who have had fragility fractures
  • Patients with evidence on imaging studies of decreased bone density or asymptomatic vertebral compression fractures incidentally noted on imaging studies
  • Patients at risk of secondary osteoporosis

Although low bone density (and the associated increased risk of fracture) can be suggested by plain x-rays, it should be confirmed by a bone density measurement.

Dual-energy X-ray absorptiometry (DXA) is used to measure bone mineral density (g/cm2); it defines osteopenia or osteoporosis (in the absence of osteomalacia), predicts the risk of fracture, and can be used to follow treatment response. Bone density of the lumbar spine, hip, distal radius, or the entire body can be measured. (Quantitative CT scanning can produce similar measurements of the spine or hip but is currently not widely available.) Bone density is ideally measured at two sites, including the lumbar spine and one hip; however, at some centers, measurements are taken of the spine and both hips.

If the spine or a hip is not available for scanning (eg, because of hardware from prior total hip arthroplasty), the distal radius can be scanned (called “1/3 radius” on the DXA scan report). The distal radius should also be scanned in a patient with hyperparathyroidism because this is the most common site of bone loss in hyperparathyroidism.

DXA results are reported as T-scores and Z-scores. The T-score corresponds to the number of standard deviations that the patient’s bone density differs from the peak bone mass of a healthy, young person of the same sex and ethnicity. The WHO establishes cutoff values for T-scores that define osteopenia and osteoporosis. A T-score < -1.0 and > -2.5 defines osteopenia. A T-score ≤ -2.5 defines osteoporosis.

The Z-score corresponds to the number of standard deviations that the patient’s bone mineral density differs from that of a person of the same age and sex and should be used for children, premenopausal women, or men < 50 yr. If the Z-score is ≤ -2.0, bone density is low for the patient’s age and secondary causes of bone loss should be considered.

Current central DXA systems can also assess vertebral deformities in the lower thoracic and lumbar spine, a procedure termed vertebral fracture analysis (VFA). Vertebral deformities, even those clinically silent, are diagnostic of osteoporosis and are predictive of an increased risk of future fractures. VFA is more likely to be useful in patients with height loss ≥ 3 cm.

The need for drug therapy is based on the probability of fracture, which depends on DXA results as well as other factors. The fracture risk assessment (FRAX) score (WHO Fracture Risk Assessment Tool 10) predicts the 10-yr probability of a major osteoporotic (hip, spine, forearm, or humerus) or hip fracture in untreated patients. The score accounts for significant risk factors for bone loss and fracture. If the FRAX score is above certain thresholds (in the US, a ≥ 20% probability of major osteoporotic fracture or 3% probability of hip fracture), drug therapy should be recommended.

  • For access to the free Fracture Risk Assessment Tool (FRAX tool) go here 10.

Monitoring for ongoing bone loss or the response to treatment with serial DXA scans should be done using the same DXA machine, and the comparison should use actual bone mineral density (g/cm2) rather than T-score. In patients with osteopenia, DXA should be repeated periodically to determine whether there is ongoing bone loss or development of frank osteoporosis requiring treatment. The frequency for follow-up DXA varies from patient to patient. DXA is often done every 2 to 3 yr but can sometimes be done less frequently, for example, if bone density is normal and fracture risk is low. In patients being treated for osteoporosis, DXA should be repeated, usually about every 2 to 3 yr, but sometimes more frequently in patients taking glucocorticoids. A stable or improved bone mineral density predicts a lower fracture risk. Monitoring bone density with a repeat DXA scan may help identify patients at higher risk of fractures due to a suboptimal response to osteoporosis treatment 9. Patients being treated for osteoporosis who have a significantly decreased bone mineral density on serial DXA examinations should be evaluated for drug adherence and secondary causes of bone loss.

When you should get a bone density (DXA) test

If you are age 65 or older, you should get a bone density test to screen for osteoporosis. If you are younger than 65 and have risk factors for osteoporosis, ask your doctor or nurse if you need a bone density test before age 65. Bone density testing is recommended for older women whose risk of breaking a bone is the same or greater than that of a 65‑year‑old white woman with no risk factors other than age. To find out your fracture risk and whether you need early bone density testing, your doctor will consider factors such as:

  • Your age and whether you have reached menopause
  • Your height and weight
  • Whether you smoke
  • Your daily alcohol use
  • Whether your mother or father has broken a hip
  • Medicines you use
  • Whether you have a disorder that increases your risk of getting osteoporosis

Plain x-rays

Bones show decreased radiodensity and loss of trabecular structure, but not until about 30% of bone has been lost. However, plain x-rays are important for documenting fractures resulting from bone loss. Loss of vertebral body height and increased biconcavity characterize vertebral compression fractures. Thoracic vertebral fractures may cause anterior wedging of the bone. In long bones, although the cortices may be thin, the periosteal surface remains smooth. Vertebral fractures at T4 or above raise concern of cancer rather than osteoporosis. Plain x-rays of the spine should be considered in older patients with severe back pain and localized vertebral spinous tenderness 11.

Glucocorticoid-induced osteoporosis is likely to cause rib fractures as well as fractures at other sites where osteoporotic fractures are common. Hyperparathyroidism can be differentiated when it causes subperiosteal resorption or cystic bone lesions (rarely). Osteomalacia may cause abnormalities on imaging tests similar to those of osteoporosis (see What is Osteopenia vs Osteoporosis : Differentiating Osteopenia, Osteoporosis and Osteomalacia).

Other testing

An evaluation for secondary causes of bone loss should be considered in a patient with a Z-score ≤ -2.0 or if a cause of secondary bone loss is clinically suspected. Laboratory testing 11 should usually include the following:

  • Serum calcium, magnesium, and phosphorus
  • 25-Hydroxy vitamin D level
  • Liver function tests, including an alkaline phosphatase (hypophosphatasia)
  • Intact PTH level (hyperparathyroidism)
  • 24-h urine for calcium and creatinine (hypercalciuria)

Other tests such as thyroid-stimulating hormone or free thyroxine to check for hyperthyroidism, measurements of urinary free cortisol, and blood counts and other tests to rule out cancer, especially myeloma (eg, serum and urine protein electrophoresis), should be considered depending on the clinical presentation.

Patients with weight loss should be screened for GI disorders (eg, malabsorption, celiac disease, inflammatory bowel disease) as well as cancer. Bone biopsy is reserved for unusual cases (eg, young patients with fragility fractures and no apparent cause, patients with chronic kidney disease who may have other bone disorders, patients with persistently very low vitamin D levels suspected of having osteomalacia).

Levels of fasting serum C-telopeptide cross-links (CTX) or urine N-telopeptide cross-links reflect increased bone resorption 11. Although reliability varies for routine clinical use, C-telopeptide cross-links and N-telopeptide cross-links may be helpful in monitoring response to therapy or with the timing of a drug holiday.

Osteoporosis treatment

Treating osteoporosis involves treating and preventing fractures, and using medication to strengthen bones.

An important objective for health services across England is to try to prevent falls and fractures, particularly in people with osteoporosis and those with risk factors for osteoporosis.

The key messages for older people and their family and carers are:

  • falls are a risk as you get older but aren’t inevitable – there are measures you can take to prevent falls or reduce the harm that might be caused by falling
    • staying active and healthy – for example, through exercise and diet – is likely to keep you independent and reduce your risk of falling
  • if you’re unsteady on your feet or you fall, speak to your doctor so that possible causes of falls, such as poor eyesight, certain medications, and poor muscle strength and balance, can be identified and treated

Although a diagnosis of osteoporosis is based on the results of your bone mineral density scan (DEXA or DXA scan), the decision about what treatment you need, if any, is also based on a number of other factors. These include your:

  • age
  • sex
  • risk of fracture
  • previous injury history

If you’ve been diagnosed with osteoporosis because you’ve had a fracture, you should still receive treatment to try to reduce your risk of further fractures.

You may not need or want to take medication to treat osteoporosis. However, you should ensure you’re maintaining sufficient levels of calcium and vitamin D. To achieve this, your healthcare team will ask you about your diet and may recommend making changes or taking supplements.

Medication for osteoporosis

A number of different medications are used to treat osteoporosis. Your doctor will discuss the treatments available and make sure the medicines are right for you.

A number of factors are taken into consideration before deciding which medication to use. These include your:

  • age
  • bone mineral density (measured by your T score)
  • risk factors for fracture

Bisphosphonates

Bisphosphonates slow the rate that bone is broken down in your body. This maintains bone density and reduces the risk of fracture.

There are a number of different bisphosphonates, including:

  • alendronate
  • ibandronate
  • risedronate
  • zoledronic acid

They’re given as a tablet or injection.

You should always take bisphosphonates on an empty stomach with a full glass of water. Stand or sit upright for 30 minutes after taking them. You’ll also need to wait between 30 minutes and 2 hours before eating food or drinking any other fluids.

Bisphosphonates usually take 6 to 12 months to work, and you may need to take them for 5 years or longer. You may also be prescribed calcium and vitamin D supplements to take at a different time to the bisphosphonate.

The main side effects associated with bisphosphonates include:

  • irritation to the esophagus (the tube that food passes through from the mouth to the stomach)
  • swallowing problems (dysphagia)
  • stomach pain

Not everyone will experience these side effects.

Osteonecrosis of the jaw is a rare side effect linked with the use of bisphosphonates, although most frequently with high-dose intravenous bisphosphonate treatment for cancer and not for osteoporosis.

In osteonecrosis, the cells in the jaw bone die, which can lead to problems with healing. If you have a history of dental problems, you may need a check-up before you start treatment with bisphosphonates. Speak to your doctor if you have any concerns.

Selective oestrogen receptor modulators (SERMs)

SERMs are medications that have a similar effect on bone as the hormone oestrogen. They help to maintain bone density and reduce the risk of fracture, particularly of the spine.

Raloxifene is the only type of SERM available for treating osteoporosis. It’s taken as a daily tablet.

Side effects associated with raloxifene include:

  • hot flushes
  • leg cramps
  • a potential increased risk of blood clots

Parathyroid hormone (teriparatide)

Parathyroid hormone is produced naturally in the body. It regulates the amount of calcium in bone.

Parathyroid hormone treatments (human recombinant parathyroid hormone or teriparatide) are used to stimulate cells that create new bone (osteoblasts). They’re given by injection.

While other medication can only slow down the rate of bone thinning, parathyroid hormone can increase bone density. However, it’s only used in a small number of people whose bone density is very low and when other treatments aren’t working.

Nausea and vomiting are common side effects of the treatment. Parathyroid hormone treatments should only be prescribed by a specialist.

Calcium and vitamin D supplements

Calcium is the major mineral found in bone, and having enough calcium as part of a healthy, balanced diet is important for maintaining healthy bones.

For most healthy adults, the recommended amount of calcium is 700 milligrams (mg) of calcium a day, which most people should be able to get from a varied diet that contains good sources of calcium.

However, if you have osteoporosis, you may need more calcium, which will usually be in the form of supplements. Ask your GP for advice about taking calcium supplements.

Vitamin D is needed to help the body absorb calcium. All adults should consume 10 micrograms (mcg) of vitamin D a day from October to March.

Because vitamin D is found in only a small number of foods, it might be difficult to get enough from your diet alone – so all adults should consider taking a daily supplement containing 10mcg of vitamin D.

Hormone replacement therapy (HRT)

HRT is sometimes recommended for women who are experiencing the menopause, as it can help control symptoms.

HRT has also been shown to maintain bone density and reduce the risk of fracture during treatment.

However, HRT isn’t specifically recommended for treating osteoporosis and isn’t often used for this purpose.

This is because HRT slightly increases the risk of developing certain conditions – such as breast cancer, endometrial cancer, ovarian cancer, stroke and venous thromboembolism – more than it lowers the risk of osteoporosis.

Discuss the benefits and risks of HRT with your doctor.

Postmenopausal hot flashes

Hot flashes, also called hot flushes, are the most common menopause symptom. As many as three out of four women experience hot flashes. Some women begin having hot flashes before menopause, when they are still getting a period 1.

Hot flashes are a sudden feeling of heat in the upper part of your body. Your face and neck may become red. Red blotches may appear on your chest, back, and arms. You may also get heavy sweating during hot flashes or cold chills after the hot flashes. Some women get more cold chills (also called cold flashes) than hot flashes.

During a hot flash, you might have:

  • A sudden feeling of warmth spreading through your upper body and face
  • A flushed appearance with red, blotchy skin
  • Rapid heartbeat
  • Perspiration, mostly on your upper body
  • A chilled feeling as the hot flash lets up

Hot flashes can vary in frequency and intensity. How long symptoms last varies greatly. On average, symptoms persist for more than seven years. Some women have them for more than 10 years.

Hot flashes are most common in women in the year before their period stops and in the year after their period stops. However, recent studies show that hot flashes can continue for up to 14 years after menopause 5. Doctors and researchers do not know why hot flashes are so common during menopause. There are medicines that can prevent some hot flashes, and there are ways you can try to manage hot flashes when they do happen.

Risk factors of hot flashes

Not all women who go through menopause have hot flashes, and it’s not clear why some women do have them. Factors that may increase your risk include:

  • Smoking. Women who smoke are more likely to get hot flashes.
  • Obesity. A high body mass index (BMI) is associated with a higher frequency of hot flashes.
  • Ethnicity. More African-American women report menopausal hot flashes than do women of European descent. Hot flashes are less common in women of Japanese and Chinese descent than in white European women.

Hot flashes treatment

Deciding whether and how to treat the symptoms of the menopause can be complicated and personal. Discuss your symptoms, family and medical history, and preferences with your doctor.

No matter what you decide, see your doctor every year to talk about your treatment plan and discuss any changes you want to make.

However, the most effective way to relieve the discomfort of hot flashes is to take estrogen, but taking this hormone carries risks. If estrogen is appropriate for you and you start it within 10 years of your last menstrual period or before age 60, the benefits can be greater than the risks.

Medications such as antidepressants and anti-seizure drugs also might help reduce hot flashes, although they’re less effective than hormones.

Discuss the pros and cons of various treatments with your doctor. If hot flashes don’t interfere with your life, you probably don’t need treatment. Hot flashes subside gradually for most women, even without treatment, but it can take several years for them to stop.

  • Consider using hormones. If you still have menstrual periods, ask your doctor about low-dose hormonal birth control. This may help your symptoms. For women who have gone through menopause, menopausal hormone therapy helps relieve hot flashes and night sweats. There are risks to menopausal hormone therapy. Ask your doctor whether it may help you. If you decide to use menopausal hormone therapy, take it for the shortest amount of time possible in the lowest dose that helps your symptoms.
  • Consider other medicines. If hormone treatments are not an option for you, ask your doctor about prescription medicines used for other health problems. Certain antidepressants, epilepsy medicine, and blood pressure medicines may help with hot flashes, even if you don’t have these specific health problems.
  • Track your hot flashes. Write down what triggers your hot flashes and try to avoid those things. Possible triggers might include spicy foods, alcohol, caffeine, stress, or being in a hot place.
  • Drink cold water. Keep ice water close by to drink when you feel a hot flash coming on.
  • Take off a layer of clothing. Dress in layers as much as possible.
  • Use a fan. Turn on a fan at night by your bed and keep one at work if possible.
  • Take deep breaths. Try taking slow, deep breaths when a hot flash starts. Slow, deep breaths tell your body that it is time to relax and be calm. This might make hot flashes shorter.
  • Lose weight. Hot flashes may be worse in women who have overweight or obesity. A recent study found that losing weight may help improve hot flashes.4

Non-Hormone Options for Treating Hot Flashes

If lifestyle changes are not enough to improve your symptoms, non-hormone options for managing hot flashes may work for you. They may be a good choice if you are unable to take hormones or if you are worried about their potential risks.

The U.S. Food and Drug Administration (FDA) has approved the use of paroxetine, a low-dose selective serotonin reuptake inhibitor (SSRI) antidepressant, to treat hot flashes. Researchers are studying the effectiveness of other antidepressants in this class.

Women who use an antidepressant to help manage hot flashes generally take a lower dose than people who use the medication to treat depression. Side effects depend on the type of antidepressant you take and can include dizziness, headache, nausea, jitteriness, or drowsiness. As with any medication, talk with your doctor about whether this is the right medication for you and how you can manage any possible side effects.

Antidepressants

A low-dose form of paroxetine (Brisdelle) is the only nonhormone treatment for hot flashes approved by the Food and Drug Administration. Other antidepressants that have been used to treat hot flashes include:

  • Venlafaxine (Effexor XR, Pristiq)
  • Paroxetine (Paxil, Pexeva)
  • Fluoxetine (Prozac, Sarafem, others)

These medications aren’t as effective as hormone therapy for severe hot flashes, but they can be helpful to women who can’t use hormones. Possible side effects include nausea, dizziness, weight gain, dry mouth or sexual dysfunction.

Other prescription medications

Other medications that might offer relief for some women include:

  • Gabapentin (Neurontin, Gralise, others). Gabapentin is an anti-seizure medication that’s moderately effective in reducing hot flashes. Side effects can include drowsiness, dizziness and headaches.
  • Clonidine (Catapres, Kapvay, others). Clonidine, a pill or patch typically used to treat high blood pressure, might provide some relief from hot flashes. Side effects include dizziness, drowsiness, dry mouth and constipation.
  • Tibolone. Tibolone (brand name Livial) is a prescription medication that is similar to taking combined hormone replacement therapy (oestrogen and progestogen). It’s taken as a tablet once a day.It can help relieve symptoms such as hot flushes, low mood and reduced sex drive, although some studies have suggested it may not be as effective as combined hormone replacement therapy.It’s only suitable for women who had their last period more than a year ago (known as the post-menopause).

    Side effects of tibolone can include tummy (abdominal) pain, pelvic pain, breast tenderness, itching and vaginal discharge.

    Risks of tibolone are similar to the risks of hormone replacement therapy, and include an increased risk of breast cancer and strokes. Talk to your doctor about the risks and benefits of tibolone if you’re considering taking it.

  • Clonidine. Clonidine is a prescription medicine that can help reduce hot flushes and night sweats in some menopausal women. It’s taken as tablets two or three times a day. It doesn’t affect hormone levels, so unlike hormone replacement therapy (HRT) it doesn’t carry an increased risk of problems such as breast cancer. But research suggests it only has a very small effect on menopausal symptoms.Clonidine can also cause some unpleasant side effects, including dry mouth, drowsiness, depression and constipation.It may take two to four weeks to notice the effects of clonidine. Speak to your doctor if your symptoms don’t improve or you experience any troublesome side effects.

Medications For Treating Hot Flashes and Night Sweats with Hormones

Some women may choose to take hormones to treat their hot flashes. A hormone is a chemical substance made by an organ like the thyroid gland or ovary. During the menopausal transition, the ovaries begin to work less and less well, and the production of hormones like estrogen and progesterone declines over time. It is believed that such changes cause hot flashes and other menopausal symptoms.

Hormone therapy steadies the levels of estrogen and progesterone in the body. It is a very effective treatment for hot flashes in women who are able to use it. There are risks associated with taking hormones, including increased risk of heart attack, stroke, blood clots, breast cancer, gallbladder disease, and dementia. The risks vary by a woman’s age and whether she has had a hysterectomy. Women are encouraged to discuss the risks with their healthcare provider.

Women who still have a uterus should take estrogen combined with progesterone or another therapy to protect the uterus. Progesterone is added to estrogen to protect the uterus against cancer, but it also seems to increase the risk of blood clots and stroke. Hormones should be used at the lowest dose that is effective for the shortest period of time possible.

  • Talk with your doctor before using hormones to treat menopause symptoms. Hormones should be used at the lowest dose and for the shortest period of time they are effective.

Hormones can be very effective at reducing the number and severity of hot flashes. They are also effective in reducing vaginal dryness and bone loss.

Hormone treatments (sometimes called menopausal hormone therapy) can take the form of pills, patches, rings, implants, gels, or creams. Patches, which stick to the skin, may be best for women with cardiac risk factors, such as a family history of heart disease.

There are many types of hormones available for women to treat hot flashes. These include estradiol, conjugated estrogen, selective estrogen receptor modulators (SERMs), and compounded or synthetic hormones. It is a common misconception that synthetic (“bioidentical”) hormones mixed by a compounding pharmacist are safer and less risky than other hormone therapies. This is not the case. We must assume they have the same risks as any hormone therapy.

Some of the relatively mild side effects of hormone use include breast tenderness, spotting or return of monthly periods, cramping, or bloating. By changing the type or amount of the hormones, the way they are taken, or the timing of the doses, your doctor may be able to help control these side effects or, over time, they may go away on their own.

Hormone therapy

Estrogen is the primary hormone used to reduce hot flashes. Women who have had a hysterectomy can take estrogen alone. But if you still have a uterus, you should take progesterone with estrogen to protect against cancer of the lining of the uterus (endometrial cancer).

With either regimen, the therapy needs to be tailored to your needs. Guidelines suggest using the smallest effective dose for symptom control. How long you use the treatment depends on the balance of your risks and benefits from hormone therapy. The goal is to optimize your quality of life.

A combination drug of bazedoxifene with conjugated estrogens (Duavee) has been approved for treating menopausal symptoms. This drug might not increase your risk of uterine cancer and might protect your bones.

Estrogen therapy isn’t a good option if you’ve had a blood clot or breast cancer.

The main benefit of hormone replacement therapy (HRT) is that it can help relieve most of the menopausal symptoms, such as:

  • hot flushes
  • night sweats
  • mood swings
  • vaginal dryness
  • reduced sex drive

Many of these symptoms pass in a few years, but they can be very unpleasant and taking hormone replacement therapy can offer relief for many women.

It can also help prevent weakening of the bones (osteoporosis), which is more common after the menopause.

Some women should not use hormones for their hot flashes.

You should not take hormones for menopausal symptoms if:

  • You have had certain kinds of cancers, like breast cancer or uterine cancer
  • You have had a stroke or heart attack, or you have a strong family history of stroke or heart disease
  • You have had blood clots
  • You have had problems with vaginal bleeding or have a bleeding disorder
  • You have liver disease
  • You have untreated high blood pressure – your blood pressure will need to be controlled before you can start hormone replacement therapy
  • You think you are pregnant or may become pregnant. It’s still possible to get pregnant while on hormone replacement therapy, so you should use contraception until two years after your last period if you’re under 50 or for one year after the age of 50
  • You have had allergic reactions to hormone medications

Talk with your doctor to find out if taking hormones to treat your symptoms is right for you.

Types of hormone replacement therapy

There are many different types of hormone replacement therapy and finding the right one for you can be tricky.
If you’re considering hormone replacement therapy, talk to your doctor about the options suitable for you, as well as possible alternatives to hormone replacement therapy.

There are different:

  • hormone replacement therapy hormones – most women take a combination of the hormones estrogen and progestogen, although women who don’t have a womb can take estrogen on its own
  • ways of taking hormone replacement therapy – including tablets, skin patches, gels and vaginal creams, pessaries or rings
  • hormone replacement therapy treatment regimens – hormone replacement therapy medication may be taken continuously without a break, or in cycles where you take estrogen continuously and only take progestogen every few weeks

Your doctor can give you advice to help you choose which type is best for you. You may need to try more than one type before you find one that works best.

Hormone replacement therapy hormones

Hormone replacement therapy replaces the hormones that a woman’s body no longer produces because of the menopause.

The two main hormones used in hormone replacement therapy are:

  • Estrogen – types used include estradiol, estrone and estriol
  • progestogen – a synthetic version of the hormone progesterone, such as dydrogesterone, medroxyprogesterone, norethisterone and levonorgestrel

Hormone replacement therapy involves either taking both of these hormones (combined hormone replacement therapy) or just taking estrogen (estrogen-only hormone replacement therapy).

Most women take combined hormone replacement therapy because taking oestrogen on its own can increase your risk of developing womb (endometrial) cancer. Taking progestogen alongside oestrogen minimises this risk.

Estrogen-only hormone replacement therapy is usually only recommended for women who have had their womb removed during a hysterectomy.

Ways of taking hormone replacement therapy

Hormone replacement therapy is available in several preparations that are taken in different ways. Talk to your doctor about the pros and cons of each option.

Tablets

Tablets, which are usually taken once a day, are one of the most common ways of taking hormone replacement therapy.

Estrogen-only and combined hormone replacement therapy tablets are available. For some women this may be the simplest way of having treatment.

However, it’s important to be aware that some of the risks of hormone replacement therapy, such as blood clots, are higher with tablets than with other forms of hormone replacement therapy (although the overall risk is still small).

Skin patches

Skin patches are also a common way of taking hormone replacement therapy. You stick them to your skin and replace them every few days. Oestrogen-only and combined hormone replacement therapy patches are available.

Patches may be a better option than tablets if you think you might find it inconvenient to take a tablet every day.

Using patches can also help avoid some side effects of hormone replacement therapy, such as indigestion, and unlike tablets they don’t increase your risk of blood clots.

Estrogen gel

Estrogen gel is an increasingly popular form of hormone replacement therapy. It’s applied to the skin once a day and is absorbed by the body.

Like skin patches, this can be a convenient way of taking hormone replacement therapy while avoiding an increased risk of blood clots.

But if you still have your womb, you’ll need to take some form of progestogen separately too, to reduce your risk of womb cancer.

Implants

Hormone replacement therapy can be given using small pellet-like implants inserted under your skin (usually in the tummy area) while your skin is numbed with local anaesthetic, although these aren’t widely available and aren’t used very often.

The implants release estrogen gradually over time and can stay in place for several months before needing to be replaced.

This may be a convenient option if you don’t want to worry about taking your treatment every day or every few days. But if you still have your womb, you’ll need to take progestogen separately too.

If you’re taking a different form of estrogen and need to take progestogen alongside it, another implant option is the intrauterine system (IUS). An IUS releases a progestogen hormone into the womb. It can remain in place for a few years and also acts as a contraceptive.

Vaginal estrogen

Estrogen is also available in the form of a cream, pessary or ring that is placed inside your vagina.

This can help relieve vaginal dryness, but won’t help with other symptoms such as hot flushes.

It doesn’t carry the usual risks of hormone replacement therapy and can be used without taking progestogen even if you still have a womb.

Hormone replacement therapy treatment regimens

Different treatment courses of hormone replacement therapy are also available, depending on whether you’re still in the early stages of the menopause or have had menopausal symptoms for some time.

The two types are cyclical (or sequential) hormone replacement therapy and continuous hormone replacement therapy.

Cyclical hormone replacement therapy

Cyclical hormone replacement therapy, also known as sequential hormone replacement therapy, is often recommended for women taking combined hormone replacement therapy who have menopausal symptoms but still have their periods.

There are two types of cyclical hormone replacement therapy:

  • monthly hormone replacement therapy – you take estrogen every day, and take progestogen alongside it for the last 14 days of your menstrual cycle
  • three-monthly hormone replacement therapy – you take estrogen every day, and take progestogen alongside it for around 14 days every three months

Monthly hormone replacement therapy is usually recommended for women having regular periods.

Three-monthly hormone replacement therapy is usually recommended for women experiencing irregular periods. You should have a period every three months.

It’s useful to maintain regular periods so you know when your periods naturally stop and when you’re likely to progress to the last stage of the menopause.

Continuous combined hormone replacement therapy

Continuous combined hormone replacement therapy is usually recommended for women who are post-menopausal. A woman is usually said to be post-menopausal if she has not had a period for a year.

As the name suggests, continuous hormone replacement therapy involves taking estrogen and progestogen every day without a break.

Estrogen-only hormone replacement therapy is also usually taken continuously.

Side effects of hormone replacement therapy

Like any medication, the hormones used in hormone replacement therapy (hormone replacement therapy) can sometimes have side effects.

Any side effects usually improve over time, so it’s a good idea to persevere with treatment for at least three months if possible.

Speak to your doctor if you experience severe side effects or they continue for longer than three months.

Side effects of estrogen

The main side effects associated with taking estrogen include:

  • bloating
  • breast tenderness or swelling
  • swelling in other parts of the body
  • nausea
  • leg cramps
  • headaches
  • indigestion
  • vaginal bleeding

These side effects will often pass in a few weeks, but the following measures may help relieve some of them in the meantime:

  • taking your estrogen dose with food may help to reduce nausea and indigestion
  • eating a low-fat, high-carbohydrate diet may reduce breast tenderness
  • regular exercise and stretching may help reduce leg cramps

If side effects persist, your doctor may recommend switching to a different way of taking estrogen (for example, changing from a tablet to a patch), changing the specific medication you’re taking, or lowering your dose.

Side effects of progestogen

The main side effects associated with taking progestogen include:

  • breast tenderness
  • swelling
  • headaches or migraines
  • mood swings
  • depression
  • acne
  • tummy (abdominal) pain
  • back pain
  • vaginal bleeding

As with side effects of estrogen, these will usually pass in a few weeks.

If they persist, your doctor may recommend switching to a different way of taking progestogen, changing the specific medication you’re taking, or lowering your dose.

Weight gain and hormone replacement therapy

Many women believe that taking hormone replacement therapy will make them put on weight, but there’s no evidence to support this claim.

You may gain some weight during the menopause, but this often happens regardless of whether you take hormone replacement therapy.

Exercising regularly and eating a healthy diet should help you to lose any unwanted weight.

More serious risks of HRT

Hormone replacement therapy has also been associated with some more serious risks, such as an increased risk of blood clots and certain types of cancer.

Breast cancer

The National Institute for Health and Care Excellence 12 says:

  • taking combined hormone replacement therapy (estrogen and progestogen) is associated with a small increased risk of breast cancer – some studies have suggested that for every 1,000 women taking combined hormone replacement therapy, there will be around five extra cases of breast cancer (from a normal risk of 22 cases of breast cancer per 1,000 menopausal women to 27)
  • the risk of breast cancer decreases when you stop taking hormone replacement therapy – estimates suggest the level of risk returns to normal after about five years
  • estrogen-only hormone replacement therapy is associated with little or no change in the risk of breast cancer

Because of the risk of breast cancer, it’s especially important to attend all your breast cancer screening appointments if you’re taking combined hormone replacement therapy.

Ovarian cancer

Studies looking at whether hormone replacement therapy can increase your risk of ovarian cancer have so far had conflicting results.

It’s thought that if there is any increase in cases of ovarian cancer in women taking hormone replacement therapy, the risk is very small.

A recent study found that for every 1,000 women taking hormone replacement therapy for five years, there will be one extra case of ovarian cancer.

Any risk of ovarian cancer is thought to decrease once you stop taking hormone replacement therapy.

Womb cancer (uterine cancer)

Estrogen-only hormone replacement therapy can increase the risk of womb cancer (also called endometrial cancer), which is why it’s only used in women who don’t have a womb (for example, because they’ve had a hysterectomy).

Taking combined hormone replacement therapy, particularly a course of continuous hormone replacement therapy (where you take both medications without a regular break), largely eliminates this risk.

If you still have a womb and you’re taking hormone replacement therapy, it’s important to take both medications as advised by your doctor to avoid increasing your risk of womb cancer.

Blood clots

Blood clots can be serious if they become lodged in a blood vessel and block the flow of blood.

The National Institute for Health and Care Excellence 12 says:

  • taking hormone replacement therapy tablets can increase your risk of blood clots
  • there’s no increased risk of blood clots from hormone replacement therapy patches or gels
  • It’s thought the risk of developing a blood clot is about two to four times higher than normal for women taking hormone replacement therapy tablets. But as the risk of menopausal women developing blood clots is normally very low, the overall risk from hormone replacement therapy tablets is still small.

It’s estimated that for every 1,000 women taking hormone replacement therapy tablets for 7.5 years, less than two will develop a blood clot.

Heart disease and strokes

The National Institute for Health and Care Excellence 12 says:

  • hormone replacement therapy doesn’t significantly increase the risk of cardiovascular disease (including heart disease and strokes) when started before 60 years of age
  • estrogen-only hormone replacement therapy is associated with no, or reduced, risk of heart disease
  • combined hormone replacement therapy is associated with little or no increase in the risk of heart disease
  • taking estrogen tablets is associated with a small increase in the risk of stroke, although the normal risk of women under 60 having a stroke is very low, so the overall risk is small

Speak to your doctor if you’re taking hormone replacement therapy or are considering taking it and are worried about the risk of stroke or heart disease.

Bioidentical or “natural” hormones

Bioidentical hormones are hormone preparations made from plant sources that are promoted as being similar or identical to human hormones.

Practitioners claim these hormones are a “natural” and safer alternative to standard hormone replacement therapy preparations.

However, bioidentical preparations aren’t recommended because:

  • they aren’t regulated and it’s not clear how safe they are – there’s no good evidence to suggest they’re safer than standard HRT
  • it’s not known how effective they are in reducing menopausal symptoms
  • the balance of hormones used in bioidentical preparations is usually based on the hormone levels in your saliva, but there’s no evidence that these levels are related to your symptoms

Many standard hormone replacement therapy hormones are made from natural sources, but unlike bioidentical hormones they’re closely regulated and have been well researched to ensure they’re as effective and safe as possible.

Unproven, Nonscientific “Treatments” for Hot Flashes

People often assume that “natural” or “herbal” products cause no harm. However, all supplements may have potentially harmful side effects, and supplements can also interact with medications you’re taking for other medical conditions. Always review what you’re taking with your doctor.

You may have heard about black cohosh, DHEA, or soy isoflavones from friends who are using them to try to treat their hot flashes. These products are not proven to be effective and some carry risks like liver damage.

Phytoestrogens are estrogen-like substances found in some cereals, vegetables, and legumes (like soy), and herbs. They might work in the body like a weak form of estrogen, but they have not been consistently shown to be effective in research studies, and their long-term safety is unclear.

At this time, it is unknown whether herbs or other “natural” products are helpful or safe. The benefits and risks are still being studied. Always talk with your doctor before taking any herb or supplement to treat your hot flashes or other menopausal symptoms.

Dietary supplements commonly used for menopause symptoms include:

  • Plant estrogens. Asian women, who consume soy regularly, are less likely to report hot flashes and other menopausal symptoms than are women in other parts of the world. One reason might be related to the estrogen-like compounds in soy. However, studies have generally found little or no benefit with soy, although research is ongoing to determine whether specific components of soy, such as genistein, help hot flashes.
  • Black cohosh. Black cohosh has been popular among many women with menopausal symptoms. Studies of black cohosh’s effectiveness have had mixed results, and the supplement might be harmful to the liver in rare circumstances.
  • Ginseng. While ginseng may help with mood symptoms and insomnia, it doesn’t appear to reduce hot flashes.
  • Dong quai. Study results indicate that dong quai isn’t effective for hot flashes. The supplement can increase the effectiveness of blood-thinning medications, which can cause bleeding problems.
  • Vitamin E. Taking a vitamin E supplement might offer some relief from mild hot flashes. In high doses, it can increase your risk of bleeding.

Nerve block procedure

A procedure known as stellate ganglian block has shown promise for treating moderate to severe hot flashes, but more research is needed. It involves injecting an anesthetic into a nerve cluster in the neck. The treatment has been used for pain management. Side effects include pain and bruising at the injection site.

Other postmenopausal symptoms and treatment

Vaginal problems and infections

Vaginal problems, such as vaginal dryness, may start or get worse in the time around menopause. Low levels of the hormone estrogen may cause your vaginal tissue to get drier and thinner. This can cause itching, burning and pain or discomfort. It also can make sex painful and cause small cuts and tears in your vagina during sex 13. Vaginal cuts or tears put you at higher risk for sexually transmitted infections (STIs, or STDs).

What you can do:

  • Vaginal moisturizer. An over-the-counter vaginal moisturizer can help keep your vagina lubricated and can make sex more comfortable. You use this every few days.
  • Vaginal lubricant. A water-based, over-the-counter vaginal lubricant can help make sex more comfortable. You use this before or during sex.
  • Prescription medicine. You can also talk to your doctor about other ways to treat your vaginal dryness, including hormonal birth control, menopausal hormone therapy, or a prescription estrogen cream, gel, or ring that is inserted into your vagina.

Problems sleeping

Many women in menopause find it hard to sleep through the night. Low levels of progesterone can make it hard to fall and stay asleep. Low estrogen levels can also cause hot flashes that make you sweat while you sleep 14. This is sometimes called night sweats. Many menopausal women get urinary symptoms that make them get up several times during sleep to urinate. You may also feel more tired than usual during the day.

What you can do

  • Exercise. One of the best ways to get a good night’s sleep is to get regular physical activity. But you may need to work out earlier in the day. Too much activity close to bedtime can make you more awake. Even if you have not exercised regularly in the past, starting to exercise during menopause may help you feel better. Studies show that certain exercises, such as yoga and stretching, may help improve hot flashes 15
  • Do not eat, drink alcohol, or smoke before bed. Avoid large meals, smoking, and drinking alcohol right before bedtime. Avoid caffeine after noon.
  • Drink warm drinks. Try drinking something warm before bedtime, such as caffeine-free tea or warm milk.
  • Limit screen-time near bedtime. Limit TV, phone, or computer use near bedtime, especially in your bedroom. The bright light of the screens tell your brain to wake up instead of sleep 16
  • Practice good sleep habits. Keep your bedroom dark, quiet, and cool. Use your bedroom only for sleep and sex, if you can.
  • Don’t nap during the day. Try to go to bed and get up at the same times every day.
  • Train your brain. If you wake during the night and can’t get back to sleep, get up and do something relaxing until you’re sleepy again.
  • Talk to your doctor or nurse. Talk to your doctor or nurse about your sleep problems, as it could be something serious. Many women develop sleep apnea or insomnia 17. Treating sleep problems can also help improve chronic pain.
  • Consider treatment for hot flashes. Talk to your doctor or nurse about treatment for your hot flashes if they are causing your sleep problems. This will usually improve your sleep.
  • Treat bladder problems. Talk to your doctor or nurse about treatment for urinary problems. Urinary or bladder incontinence is not a normal part of the aging process. There are treatments that work.

Memory problems

You might become forgetful or have trouble focusing. As many as two-thirds of women going through perimenopause say they have problems with memory or trouble focusing 18. Menopausal hormone therapy does not treat or prevent memory loss or brain diseases, including dementia and Alzheimer’s disease. In a recent study, memory problems were linked to depression and loss of sleep but not to levels of the hormone estrogen 18.

What you can do

  • Get enough sleep and physical activity, eat healthy and don’t smoke. This may improve memory 19
  • Stay socially active. Join a group or club that focuses on activities you enjoy, such as a hiking club or a quilting bee. Social interaction may help delay memory loss and prevent diseases such as dementia and Alzheimer’s disease 20
  • Stay mentally active. You may be able to boost your memory and focus by doing mental activities like crossword puzzles, taking a class, or learning a new skill like a foreign language.
  • Talk to your doctor if forgetfulness or other mental problems affect your daily life.

Urinary problems

Many women develop bladder or urinary problems during menopause. Lower estrogen levels may weaken the urethra. Some women find it hard to hold their urine long enough to get to the bathroom. This is called urinary urge incontinence. Urine might also leak out when you sneeze, cough, or laugh. This is called urinary stress incontinence. Some women have disrupted sleep during menopause because of the need to urinate during sleep. Urinary problems after menopause are not a normal part of aging and can be treated.

What you can do

  • Treatment for urinary incontinence can include limiting or avoiding caffeine, taking medicine, using special medical devices, physical therapy, or having surgery, depending on the cause of the condition.
  • If you have urine leakage, you can try urinary incontinence products such as pads, a urethra cap, or a pessary. A urethra cap fits over your urinary opening. It is reusable. A pessary is a round disk that is inserted into your vagina to support your bladder. Your doctor or nurse will fit you for your pessary, but you can remove, wash, and reinsert it yourself.
  • Talk to your doctor or nurse about things you can do at home to help treat urinary incontinence. These may include a special kind of exercise for your pelvic floor muscles called Kegel exercises. Your doctor or nurse may also suggest losing weight, since extra weight puts more pressure on your bladder and nearby muscles.

Mood changes

You might feel irritable or have crying spells. If you had mood changes with your monthly periods or depression after giving birth, you may be more likely to have mood changes with menopause, too 21. Even if you never experienced mood changes during your monthly periods or after giving birth, you may still get mood changes during menopause. Mood changes at this time also could be from stress, family changes, or feeling tired. Mood changes are not the same as depression.

What you can do

  • Try to get seven to eight hours of sleep.
  • Get active to help you feel your best. Find ways to get active.
  • Avoid taking on too many duties as much as possible. Look for positive ways to ease your stress.
  • Join a support group online or in your community with women who are also going through menopause.
  • Talk to your doctor or nurse about menopausal hormone therapy, which can help with mild mood changes. All medicines have risks, including menopausal hormone therapy. Mood changes that happen during menopause are usually not the same as depression, which is a different, serious illness that also needs treatment.

Depression and anxiety

Your risk for depression and anxiety is higher during the time around menopause. This may be caused by changing hormones, menopausal symptoms, or both. You may experience sadness or depression over the loss of fertility or the changes in your body. If you have symptoms of depression or anxiety, see your doctor. Your doctor may recommend therapy or medicine or both to treat depression or anxiety.

What you can do

  • Sleep. Try to get enough sleep. Most adults need between seven and eight hours of sleep each night. Lack of sleep is linked to depression 17
  • Exercise. Get at least 30 minutes of physical activity on most days of the week. Exercise is proven to help with depression. See our Fitness section for tips on how to get active.
  • Limit alcohol. Limit how much alcohol you drink, if any. A moderate amount of alcohol for women is one drink a day, and no more than seven drinks in a week. More than four drinks at a time is considered binge drinking.
  • Lower stress. Set limits for how much you take on. Look for positive ways to unwind and ease daily stress. Try relaxation techniques, reading a book, spending some quiet time outdoors, or other healthy ways to unwind.

Changing feelings about sex

Some women feel more comfortable with their sexuality after menopause. Others may feel less aroused. You may feel less interested in sex if it is uncomfortable or painful. This can happen because of drier or thinner vaginal tissue.

Menopause may cause changes in your sex life, or you may not notice any changes at all. Here are some possible changes:

  • Lower hormone levels can make your vaginal tissue drier and thinner. This condition, called vaginal atrophy, can make sex uncomfortable or painful.
  • Lower hormones may lower your sex drive. It may take you longer to get aroused.
  • Night sweats can disturb your sleep and make you tired.
  • Emotional changes can make you feel stressed or irritable.

Being less interested in sex as you get older is not a medical condition that requires treatment. But if changes in your sexual health bother you, talk to your doctor or nurse about ways to help, such as treatments to relieve vaginal dryness.

What you can do

  • If you are bothered by vaginal dryness, there are safe over-the-counter and prescription treatments to improve vaginal lubrication.
  • Some women are less interested in sex during menopause because of other menopause symptoms such as depression, anxiety, or lack of sleep. Talk with your doctor or nurse about possible treatments if your menopause symptoms bother you.
  • Be active. Physical activity can boost your energy levels, lift your mood, and improve your body image. All of these can help increase your interest in sex.
  • Don’t smoke. Cigarette smoking can reduce blood flow to the vagina and lower the effects of estrogen. This can make it more difficult to get aroused.
    Avoid drugs and alcohol. They can slow down how your body responds.
  • Have sex more often. If you choose to have sex, it can increase blood flow to your vagina and help keep tissues healthy.
  • Allow time to become aroused during sex. Moisture from being aroused protects tissues and makes sex more comfortable.
  • Practice pelvic floor exercises. These can increase blood flow to the vagina and strengthen the muscles involved in orgasm. Learn more about pelvic floor exercises.
  • Avoid products that irritate your vagina. Bubble bath and strong soaps might cause irritation. See your doctor or nurse if you have vaginal itching or irritation as it may be a sign of infection.
  • Talk to your doctor or nurse about products to increase your sex drive if you are bothered by a low level of interest in sex. Some women try products like pills or creams with the male hormone testosterone or similar products. The Food and Drug Administration (FDA) has not approved these products for treating low female sex drive. But, the FDA has approved flibanserin, a medicine to treat low sexual desire. If you take flibanserin, you cannot drink alcohol because of its risks for serious low blood pressure problems and loss of consciousness. Flibanserin can increase the number of times you have a satisfying sexual experience by once a month or once every two months. Talk to your doctor about the benefits and other risks of taking any medicine.

For vaginal dryness that causes mild discomfort during sex:

  • Use an over-the-counter, water-based vaginal lubricant when you have sex.
  • Try an over-the-counter vaginal moisturizer to help increase moisture. You may need to use it every few days.

For more severe vaginal dryness, your doctor might prescribe medicines that you put into your vagina to increase moisture and sensation. These may include 22:

  • Vaginal estrogen creams
  • Estrogen tablets or rings for insertion into the vagina
  • A non-hormonal medicine called ospemifene 23

Discuss your symptoms and personal health issues with your doctor or nurse to decide whether one or more treatment options are right for you.

  1. Shifren, J.L., Gass, M.L.S., for the NAMS Recommendations for Clinical Care of Midlife Women Working Group. (2014). The North American Menopause Society Recommendations for Clinical Care of Midlife Women. Menopause; 21(10): 1038–1062.[][][]
  2. Mishra, G.D., Cooper, R., Tom, S.E., Kuh, D. (2009). Early life circumstances and their impact on menarche and menopause. Womens Health; 5: 175–190.[]
  3. Avis, N.E., McKinlay, S.M. (1991). A longitudinal analysis of women’s attitudes toward the menopause: Results from the Massachusetts Women’s Health Study (link is external). Maturitas; 13: 65–79.[]
  4. Smoking’s Impact on Women’s Health. https://women.smokefree.gov/quit-smoking/what-women-should-know/smokings-impact-on-women[]
  5. Tepper, P.G., Brooks, M.M., Randolph, J.F., Crawford, S.L., Khoudary, E., Gold, E.B., et al. (2016). Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause; 23(10): 1067–1074.[][]
  6. Becker, R.C. (2005). Heart attack and stroke prevention in women (link is external). Circulation; 112: e273–e275.[]
  7. Crandall, C., Aragaki, A., Cauley, J., Manson, J., LeBlanc, E., Wallace, R., et al. (2015). Associations of Menopausal Vasomotor Symptoms with Fracture Incidence (link is external). Journal of Clinical Endocrinology and Metabolism; 100(2): 524–534.[]
  8. Jackson, L.W., Cromer, B.A., Panneerselvamm, A. (2010). Association between bone turnover, micronutrient intake, and blood lead levels in pre-and postmenopausal women, NHANES 1999–2002. Environmental Health Perspectives; 118(11): 1590–1596.[]
  9. Leslie WD, Majumdar SR, Morin SN, Lix LM: Change in bone mineral density is an indicator of treatment-related antifracture effect in routine clinical practice: A registry-based cohort study. Ann Intern Med 165(7):465–472, 2016. doi: 10.7326/M15-2937. http://annals.org/aim/article/2534408/change-bone-mineral-density-indicator-treatment-related-antifracture-effect-routine[][]
  10. Centre for Metabolic Bone Diseases, University of Sheffield, UK. Fracture Risk Assessment Tool. https://www.sheffield.ac.uk/FRAX/tool.jsp[][]
  11. Merck Sharp & Dohme Corp., Merck Manual. Osteoporosis. https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/osteoporosis/osteoporosis[][][]
  12. The National Institute for Health and Care Excellence. https://www.nice.org.uk/[][][]
  13. Muhleisen, A. L., Herbst-Kralovetz, M. M. (2016). Menopause and the vaginal microbiome. Maturitas; 91:42-50.[]
  14. Kravitz, H. M., Ganz, P. A., Bromberger, J., Powell, L. H., Sutton-Tyrrell, K., Meyer, P. M. (2003). Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause; 10, 19–28.[]
  15. Innes, K.E., Selfe, T.K., Vishnu, A. (2010). Mind-body Therapies for Menopausal Symptoms: A Systematic Review. Maturitas; 66(2): 135-149.[]
  16. Lights Out for a Good Night’s Sleep. https://www.sleepfoundation.org/sleep-news/lights-out-good-nights-sleep[]
  17. Eichling, P.S., Sahni, J. (2005). Menopause Related Sleep Disorders (link is external). Journal of Clinical Sleep Medicine; 1(3): 291–300.[][]
  18. Weber, M., Mapstone, M., Staskiewicz, J., Maki, P.M. (2012). Reconciling subjective memory complaints with objective memory performance in the menopausal transition. Menopause; 19: 735–741.[][]
  19. Gardener, H., Wright, C. B., Dong, C., Cheung, K., DeRosa, J., Nannery, M., … Sacco, R. L. (2016). Ideal Cardiovascular Health and Cognitive Aging in the Northern Manhattan Study. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 5(3), e002731.[]
  20. Ertel, K.A., Glymour, M.M., Berkman, L.F. (2008). Effects of Social Integration on Preserving Memory Function in a Nationally Representative US Elderly Population. American Journal of Public Health; 98(7): 1215–1220.[]
  21. Roberts, H., Hickey, M. (2016). Managing the menopause: An update. Maturitas. 201;86:53-8.[]
  22. North American Menopause Society Position Statement. (2013). Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause; 20: 888–902.[]
  23. https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=203505[]
read more
Health topics

PMS

PMS
What is PMS PMS commonly called premenstrual syndrome or premenstrual tension (PMT), is a group of symptoms that start one to two weeks before your
read more
1 368 369 370 371 372 544
Page 370 of 544
Health Jade